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ABSTRACT 
 
Acute pancreatitis (AP), a common cause of acute abdominal pain, is usually a mild, self-
limited disease. However, some 20-30% of patients develop a severe disease manifested by 
pancreatic necrosis, abscesses or pseudocysts, and/or extrapancreatic complications, such 
as vital organ failure (OF). Patients with AP develop systemic inflammation, which is 
considered to play a role in the pathogenesis of multiple organ failure (MOF). OF mimics the 
condition seen in patients with sepsis, which is characterized by an overwhelming production 
of inflammation mediators, activation of the complement system and systemic activation of 
coagulation, as well as the development of disseminated intravascular coagulation (DIC) 
syndrome. In systemic inflammation, an excessive proinflammatory burst is rapidly followed 
by an anti-inflammatory reaction that may result in immune suppression. Similarly, rapid 
activation of coagulation may turn into global or selected exhaustion of physiological 
anticoagulant systems. Vital OF is the major cause of mortality in AP, along with infectious 
complications. About half of the deaths occur within the first week of hospitalization and thus, 
early identification of patients likely to develop OF is important.  
The aim of the present study was to investigate inflammatory and coagulation disturbances 
in AP and to find inflammatory and coagulation markers for predicting severe AP, and 
development of OF and fatal outcome. 
This clinical study consists of four parts. All of patients studied had AP when admitted to 
Helsinki University Central Hospital. In the first study, 31 patients with severe AP were 
investigated. Their plasma levels of protein C (PC) and activated protein C (APC), and 
monocyte HLA-DR expression were studied during the treatment period in the intensive care 
unit; 13 of these patients developed OF. In the second study, the serum levels of 
complement regulator protein CD59 were studied in 39 patients during the first week of 
hospitalization; 12 of them developed OF. In the third study, 165 patients were investigated; 
their plasma levels of soluble form of the receptor for advanced glycation end products 
(sRAGE) and high mobility group box 1 (HMGB1) protein were studied during the first 12 
days of hospitalization; 38 developed OF. In the fourth study, 33 patients were studied on 
admission to hospital for plasma levels of prothrombin fragment F1+2 and tissue factor 
pathway inhibitor (TFPI), and thrombin formation capacity by calibrated automated 
thrombogram (CAT); 9 of them developed OF. 
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Our results showed significant PC deficiency and decreased APC generation in patients with 
severe AP. The PC pathway defects seemed to be associated with the development of OF. 
In patients who developed OF, the levels of serum CD59 and plasma sRAGE, but not of 
HMGB1, were significantly higher than in patients who recovered without OF. The high CD59 
levels on admission to the hospital seemed to be predictive for severe AP and OF. The 
median of the highest sRAGE levels was significantly higher in non-survivors than in 
survivors. The in vivo thrombin generation was estimated by means of F1+2 levels, and no 
significant difference between the patient groups was found in these levels. The 
thrombograms of all patients were disturbed in their shape, and in 11 patients the exogenous 
tissue factor (TF) did not trigger thrombin generation at all (‘flat curve’). All of the patients that 
died displayed a flat curve. Free TFPI levels and free/total TFPI ratios were significantly 
higher in patients with a flat curve than in the others, and these levels were also significantly 
higher in non-survivors than in survivors. The flat curve in combination with free TFPI 
seemed to be predictive for a fatal outcome in AP. 
In conclusion, a significant PC pathway pathology was demonstrated in severe AP, and 
these defects were more frequent in patients who developed OF. Failure of TF-initiated 
thrombin generation in the thrombogram assay, explained by high levels of circulating free 
TFPI, was  associated with OF and mortality in AP. Increased serum and plasma levels of 
CD59 and sRAGE were associated with severe AP with OF, and increased CD59 levels 
seemed to be predictive for severe AP and OF.  
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1 INTRODUCTION 
 
Acute pancreatitis (AP) is a common cause of abdominal pain. Its annual incidence is 
increasing, and is currently high in Finland; 102 episodes per 100,000 inhabitants (Pelli et al 
2009). The clinical diagnosis of AP is based on characteristic epigastric pain and nausea or 
vomiting, combined with elevated serum levels of amylase (>3 times the upper reference 
limit) and/or typical AP imaging findings on computed tomography (CT) (Banks et al 2006). 
The most common etiology of AP is alcohol abuse or gallstones, in about 70-80% of all 
cases (Forsmark et al 2007). AP is usually a mild, self-limited disease with a low mortality 
rate. However, about 20% of AP cases are severe, with a high mortality rate of 10-25% 
(Swaroop et al 2004). According to the Atlanta classification, severe AP is defined by the 
presence of local complications (necrosis, pseudocysts or abscesses) and/or organ failure 
(OF) (shock, pulmonary insufficiency and renal failure) (Bradley 1993). 
Multi-factorial scoring systems, based on clinical and laboratory findings, have been 
developed for assessing the severity of AP. These are: Ranson’s score (Ranson et al 1974), 
Glasgow/Imrie score (Blamey et al 1984) and the Acute Physiology and Chronic Health 
Evaluation II (APACHE II) score (Knaus et al 1985)). For predicting mortality, organ 
dysfunction scores (Multiple Organ Dysfunction Score (MODS) (Marshall et al 1995) and the 
Sequential Organ Failure Assessment (SOFA) score (Vincent et al 1998)) have been used. 
These scoring systems are nevertheless often too complex to use in clinical practice.  
There is no specific treatment for AP, and currently the therapy is mainly supportive. This 
includes adequate fluid resuscitation, monitoring for hypoxemia, and pain relief. Nearly half of 
the patients with severe AP have OF and therefore require management in the intensive care 
unit (Swaroop et al 2004). OF appears to be the most important factor leading to morbidity 
and mortality in AP (Banks et al 2006). Early recognition and assessment of the severity of 
AP are thus important, so that aggressive treatment can be started. Despite numerous 
attempts to find accurate predictive laboratory and imaging parameters or scoring systems 
(Tenner 2004; Banks et al 2006), these still present a challenge for clinicians.  
The exact pathogenesis of AP is only partly known, but the key event is the intra-acinar 
activation of trypsinogen-inducing autodigestion of the pancreas and intrapancreatic 
inflammation. This can progress to systemic inflammation and cause multiorgan failure 
(MOF) (Banks et al 2006). Coagulation disorders (mainly consumptive coagulopathy and 
hyperfibrinolysis (Lasson and Ohlsson 1986a; Lasson and Ohlsson 1986b)) are known to 
occur in severe AP; they are related to the severity and to organ dysfunction. In the 
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pathogenesis of pancreatic necrosis, the pancreatic perfusion and hypoxia seem to play an 
important role. There is increasing evidence that microvascular disturbances 
(vasoconstriction, shunting, increased permeability, inadequate perfusion, and increased 
blood viscosity and coagulation) are significant events in the progression of AP, and that 
reduced tissue blood flow in AP is related to severity. (Cuthbertson and Christophi 2006)  
The present clinical study investigates inflammatory and coagulation disturbances in AP. At 
the same time, we wanted to study whether these disturbances are associated with the 
severity of AP, the development of OF, and the outcome of the patients, and also, whether 
we could find any predictive inflammatory or coagulation markers.  
 
 
15 
 
2 REVIEW OF THE LITERATURE 
 
2.1 Clinical manifestations and classification 
AP is a common clinical condition (approximately 2-5% of the cases of acute abdominal 
disorders (Leppaniemi and Haapiainen 2006)) and its onset is usually acute. The main 
symptoms are epigastric pain; usually radiating to the back; nausea, vomiting, fever and 
tachycardia. All patients may not experience pain, however, and it has been noted that in 30-
40% of patients the diagnosis of AP has only been made at autopsy (Forsmark et al 2007).
Physical signs of severe disease such as ecchymoses in the flank (Gray-Turner’s sign) or in 
the periumbilical region (Cullen sign) occurs in less than 3% of patients, and have been 
associated with a mortality of 37% (Meyers et al 1989). The clinical suspicion of AP is 
supported by the finding of an elevated serum amylase level.  
AP is associated with significant morbidity and mortality. Today, the overall mortality rate of 
AP is about 2-5% (Figure 1) (Russo et al 2004; Pandol et al 2007). The mortality rate is 
higher in patients with necrotizing AP (approximately 17%) compared to those with interstitial 
AP (3%) (Pandol et al 2007).
 
Figure 1. Acute pancreatitis, classification and mortality rates.
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A widely accepted and used clinical classification system for AP was completed in an 
international symposium held in Atlanta, Georgia, in September 1992 (Bradley 1993). 
According to the Atlanta classification AP is divided into a mild and a severe disease form. 
The majority of cases (70-80%) are mild. Mild AP is characterized by inflammation and 
edema of the pancreas, interstitial pancreatitis (focal or diffuse enlargement of the pancreas) 
with no or little necrosis. It is usually a self-limiting disease and does not require any special 
treatment. 
About 20% of AP cases are severe, with a rather high mortality rate, 10-25% (Isenmann et al 
2001; Swaroop et al 2004). According to the Atlanta classification, severe AP is defined by 
the presence of local complications (necrosis, pseudocysts or abscesses) and/or OF (shock, 
pulmonary insufficiency and renal failure) (Bradley 1993). The mortality rate of patients with 
necrotizing AP is greater (ca 30%) in those with infected necrosis than in those with sterile 
necrosis (12%), and the prevalence of infected necrosis is approximately 15-20% (Pandol et 
al 2007).  
 
Nearly half of the patients with severe AP have OF, and thus require management in the 
intensive care unit (Swaroop et al 2004; Banks et al 2006). The prevalence of OF is the 
same or somewhat higher in infected necrosis (34-89%) than in sterile necrosis (45-73%) 
(Banks et al 2006). In the Atlanta classification, the definition of OF includes shock (systolic 
blood pressure <90 mmHg), pulmonary insufficiency (PaO2 <60 mmHg), renal failure (serum 
creatinine level >2 mg/dl), and gastrointestinal bleeding (>500 ml blood loss within 24 h) 
(Bradley 1993). OF appears to be the most important factor leading to morbidity and mortality 
(Banks et al 2006). In the presence of single OF, mortality is generally less than 10%, 
whereas in MOF the mortality rate is 35-50% (Pandol et al 2007). The first sign of MOF is 
often impaired lung function due to adult respiratory distress syndrome (ARDS) (Bhatia et al 
2000). If OF is present already at admission to the hospital (early OF), the mortality rate is 
high (42%) and progresses to MOF in 79% of the patients (Isenmann et al 2001). In early 
OF, the mortality rate of patients with persistent OF (lasting >48 h) is 35%, but if the OF is 
transient (<48 h), or in severe AP without OF, the mortality rate is similar to that in mild AP 
(approximately 3%) (Johnson and Abu-Hilal 2004). About one half of the patients who die 
from AP, die within the first 1-2 weeks from a severe initial attack due to systemic 
inflammatory response syndrome (SIRS) and MOF. Patients who have a severe attack but 
survive beyond this period later develop infection complications, e.g. necrotic tissue infection 
leading to sepsis and SIRS and MOF. (McKay et al 1999; Pandol et al 2007) 
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Significant advances have been made in understanding the mechanism of action in OF since 
the Atlanta classification was published. It is now clear that this classification does not 
distinguish between the severity or reversible nature of the OF. The Atlanta classification has 
been criticized, and several authors have emphasized that the criteria should be revised 
(Vege and Chiari 2005; Bollen et al 2007; Rau 2007; Bollen et al 2008). 
 
2.2 Epidemiology of acute pancreatitis 
There are very few epidemiological studies on large patient populations with AP. Comparing 
the results of different reports is difficult, because some studies report the incidence of only 
the first attacks of AP, while others include also recurrent attacks. The annual incidence of 
AP has been found to be on the rise (Corfield et al 1985; Jaakkola and Nordback 1993; 
McKay et al 1999; Lindkvist et al 2004; Frey et al 2006; Yadav and Lowenfels 2006; Sandzen 
et al 2009), particularly in gallstone AP (Yadav and Lowenfels 2006), and to vary 
considerable in different countries. It is reported  in the UK to be 7.3-31.8 (Corfield et al 1985; 
Thomson et al 1987; McKay et al 1999), in Sweden 23.4-38.2 (Appelros and Borgstrom 
1999; Sandzen et al 2009), in the Netherlands 16 (Eland et al 2000), in Germany 20 
(Lankisch et al 2002), in the USA 43.8 (Frey et al 2006), and in Finland it is one of the 
highest 73.4-102 (Jaakkola and Nordback 1993; Pelli et al 2009) per 100,000 inhabitants. 
The cause of this increased incidence has been speculated: for instance, increased alcohol 
consumption, greater accuracy of diagnosis, and an increased prevalence gallstones and 
obesity have been suggested to be possible causes (Jaakkola and Nordback 1993; Appelros 
and Borgstrom 1999; Lindkvist et al 2004). The mean age at the first attack of AP is 60 
years, and the sex distribution is almost equal (Corfield et al 1985; Thomson et al 1987; 
Yadav and Lowenfels 2006). The mortality from AP has been reported to have decreased 
(Jaakkola and Nordback 1993; Lankisch et al 1996; McKay et al 1999) or to be stable. 
(Gronroos and Nylamo 1999) Increasing age is associated with higher mortality (Corfield et 
al 1985; McKay et al 1999). However, the higher mortality in elderly persons has been found 
to be associated with concomitant medical or surgical diseases, rather than complications of 
AP (Fan et al 1988). The mortality rate of patients with recurrent disease has been found to 
be lower than that of patients with first attacks (Appelros and Borgstrom 1999), and the 
proportion of recurrent attacks of all cases has been as high as 21% (Cavallini et al 2004). 
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2.3 Etiology of acute pancreatitis 
The most common etiology of AP is alcohol abuse or gallstones, comprising about 70-80% of 
all cases (Forsmark et al 2007). In up to 10% of the cases, the cause of AP still remains 
unknown (idiopathic AP) (Tonsi et al 2009), and other causes (e.g. hypercalcemia, 
hypertriglyceridemia, trauma, drugs, infections, endoscopic retrograde 
cholangiopancreatography (ERCP), developmental abnormalities, tumors, hereditary and 
autoimmune causes) are uncommon or controversial (Kemppainen and Puolakkainen 2007; 
Tonsi et al 2009; Wang et al 2009). The predominant etiology varies in different countries 
(Corfield et al 1985; Lankisch et al 1996; Appelros and Borgstrom 1999; Cavallini et al 2004; 
Lindkvist et al 2004; Frey et al 2006; Yadav and Lowenfels 2006). Alcohol is the most 
common cause of AP in Finland, and alcohol consumption correlates with the incidence of 
AP (Jaakkola and Nordback 1993). In Sweden, gallstones are the most common cause in 
first attacks (Lindkvist et al 2004) and alcohol in recurrent attacks of AP (Appelros and 
Borgstrom 1999; Sandzen et al 2009). AP caused by alcohol has been found to be more 
common in men, gallstone AP in women, and idiopathic AP is similar in both sexes (Yadav 
and Lowenfels 2006; Tonsi et al 2009). 
 
2.4 Diagnosis of acute pancreatitis 
The clinical diagnosis of AP is based on characteristic epigastric pain and nausea or 
vomiting, combined with elevated serum levels of amylase (>3 times the upper reference 
limit) and/or typical AP imaging findings on CT (Banks et al 2006). 
There are no specific and exact laboratory tests for AP, but testing for elevated 
serum/plasma levels of amylase and/or lipase is used. The measurement of amylase is used 
more widely, and a level of at least 3 times the upper reference limit is suggested to be the 
most accurate cutoff (Forsmark et al 2007). In clinical studies, the sensitivity of serum 
amylase estimation has been 45-85% and specificity 91-99% (Gumaste et al 1993; 
Kemppainen et al 1997; Treacy et al 2001). Correspondingly, the sensitivity of serum lipase 
estimation has been 67-100% and specificity 96-97% (Gumaste et al 1993; Treacy et al 
2001). Measurements of other enzymes (including pancreatic isoamylase, phospholipase 2, 
elastase 1 and trypsinogen-2) in serum or urine have also been proposed as diagnostic tools 
for AP (Forsmark et al 2007). A rapid urinary trypsinogen-2 test strip has been developed; it 
has proved to be highly sensitive in distinguishing AP patients. A negative result can rule out 
AP with a very high probability (Kemppainen et al 1997; Kylanpaa-Back et al 2002b). 
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CT is often used as the gold standard for confirming the diagnosis of AP. In addition, CT is 
effective in excluding alternative diagnoses, in determining the severity of AP, and in 
identifying complications (Forsmark et al 2007). The primary role of ultrasonography (US) in 
the diagnosis of AP is to identify gallstones or dilation of the common bile duct due to 
choledocholithiasis. (Banks et al 2006) Magnetic resonance imaging (MRI) is as accurate as 
CT in imaging the pancreas and assessing the stage of severity of AP (Clancy et al 2005; 
Forsmark et al 2007). (Morgan 2008) 
 
2.5 Severity assessment of acute pancreatitis 
On admission to hospital it is difficult to predict whether a given patient’s disease will take a 
mild or a severe course. This would, however, be most important so as to screen patients 
with severe disease and treat them in the intensive care unit. A variety of predictive systems 
have been developed for this purpose, including the measurement of markers in serum and 
urine (Mayer et al 2000; Granger and Remick 2005; Beger and Rau 2007), CT (Balthazar et 
al 1990), and multiple factor scoring systems. Most of the scoring systems are unfortunately 
too complicated, insufficiently sensitive, or not available soon enough.  
There are some clinical predictors and laboratory markers of poor outcome in AP. High age 
is one predictive factor for mortality (Corfield et al 1985; McKay et al 1999), and early and 
persistent (>48 h) OF is another predictive factor for mortality (Isenmann et al 2001; Johnson 
and Abu-Hilal 2004; Beger and Rau 2007). Obesity is a risk factor for severe AP (Martinez et 
al 2006), and pancreatic necrosis is a risk factor for severe outcome as well (Balthazar et al 
1990; Simchuk et al 2000). The role of early and/or sustained hemoconcentration in 
predicting severe AP and/or OF has also been studied in humans. Baillargeon et al. 
(Baillargeon et al 1998) found that hemoconcentration with an admission hematocrit >/= 47% 
or failure of admission hematocrit to decrease at 24 h were risk factors for the development 
of pancreatic necrosis. However, these hematocrit values were not predictive of OF. There 
are other studies with similar results (Brown et al 2000; Gan and Romagnuolo 2004), but 
also studies with controversial results (Lankisch et al 2001; Remes-Troche et al 2005; 
Gardner et al 2006). Two of the ones with controversial results (Lankisch et al 2001; Gardner 
et al 2006) found that the absence of admission hemoconcentration had a strong negative 
predictive value for necrosis. In one study, a high serum creatinine level (>2.0 mg/dl) and/or 
marked hyperglycemia (>250 mg/dl) on admission were shown to predict mortality (Blum et 
al 2001). C-reactive protein (CRP) has been widely used as a predictor of severe AP (cutoff 
150 mg/l), but only measurement at 48 h after admission has been shown to be reasonably 
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accurate (Rettally et al 2003; Mofidi et al 2006). Among the biochemical markers of 
significance, IL-6, IL-10, procalcitonin (PCT) and trypsinogen-activation peptide (TAP) are 
most likely to be used in clinical practice as predictors of severity (Kylanpaa-Back et al 
2002a; Mofidi et al 2009). A combination of plasma IL-10 and serum calcium measurements 
has been shown to predict OF with high accuracy at hospital admission (Mentula et al 2005). 
Multi-factorial scoring systems have been used to assess severity. These are, e.g.: Ranson’s 
score (Ranson et al 1974), Glasgow/Imrie score (Blamey et al 1984) and the APACHE II 
score (Knaus et al 1985) based on clinical and laboratory findings. For predicting mortality, 
organ dysfunction scores (MODS (Marshall et al 1995) and SOFA score (Vincent et al 1998)) 
have been used. An APACHE II score that rises during the first 48 h is strongly suggestive of 
the development of severe AP, whereas an APACHE II score that falls within the first 48 h 
predicts mild AP (Banks et al 2006). One scoring system that rapidly identifies patients with a 
mild disease form has been developed for harmless acute pancreatitis (HAPS). It is based on 
three parameters (absence of rebound tenderness/guarding, e.g. no signs of peritonitis, 
normal serum creatinine level, and normal hematocrit level). The HAPS has shown high 
specificity (97%) and positive predictive value (98%), but quite low sensitivity (29%) and a 
negative predictive value (20%). (Lankisch et al 2009) 
 
2.6 Pathogenesis of acute pancreatitis and clinical manifestations  
Although alcohol abuse and gallstones account for the majority of the cases of AP, the exact 
mechanisms by which these factors initiate AP are presently unknown. Despite the 
etiological factors in the pathogenesis of AP, the initial insult is probably the premature 
intracellular activation of digestive enzymes (proteases) leading to autodigestion of pancreas. 
The disease progression is a three-phase continuum: local inflammation of the pancreas, a 
generalized inflammatory response (SIRS), and the final stage of MOF in the most severe 
form of AP (Makhija and Kingsnorth 2002). (Bhatia et al 2005) 
The most common theory is that AP develops as a result of an injury of acinar cells, 
consequently permitting the leakage of pancreatic enzymes (trypsin, chymotrypsin and 
elastase) into pancreatic tissue, where they become activated and initiate autodigestion of 
pancreas. The activated proteases (trypsin, elastase and lipase) break down tissue and cell 
membranes, causing edema, vascular damage, hemorrhage, necrosis and a local 
inflammatory reaction. The key propagating factor is thought to be microvascular 
derangement (including vasoconstriction, shunting, inadequate perfusion, increased 
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permeability, and increased blood viscosity, coagulation, and adhesion and activation of 
leukocytes that can cause occlusions in the venules and microthrombus formation), the 
extent of which influences also the severity of the disease. These processes may be caused 
or exacerbated by an ischemia-reperfusion injury and the development of oxygen-derived 
free radicals. (Cuthbertson and Christophi 2006)  
Derangement in the coagulation cascade is likely to be at least partially due to systemic 
inflammation, but it may also represent a coagulation failure that parallels MOF.  
The current knowledge of the pathogenesis of AP is based mostly on studies using animal 
models. Because the clinical disease varies widely in regard to its course and severity, and 
there is hardly no access to examine the pancreatic tissue during AP, several animal models 
have been developed. In these models AP is caused by parenteral administration of 
cholecystokinin analogues or arginine, pancreatic duct obstruction, bile acid perfusion of the 
pancreatic duct, a choline-deficient and ethionine-supplemented diet, and a combination of 
an alcohol diet and parenteral administration of cholecystokinin analogues. (Pandol et al 
2007)  
 
2.6.1 Zymogen activation 
The pancreatic digestive enzymes are synthesized and stored as inactive zymogens in 
acinar cells. Normally these enzymes are secreted into the duodenum, where the intestinal 
endopeptidase (enterokinase) hydrolyses trypsinogen, releasing TAP and activating trypsin. 
In the secretory granules of acinar cells, the autoactivation of trypsinogen is inhibited by 
pancreatic secretory trypsin inhibitor (PSTI). (Naruse 2003) The intra-acinar activation of 
zymogens is a key event in the pathogenesis of AP (Figure 2). Several pathways are 
thought to be involved in the intracellular conversion of pancreatic zymogens to active 
enzymes. These include: 1) trypsinogen autoactivation to trypsin, 2) cleavage of trypsinogen 
to trypsin by lysosomal hydrolase cathepsin B (CTBS), 3) diminished activity of intracellular 
pancreatic trypsin inhibitory, 4) leakage of zymogens and lysosomal enzymes into the 
cytoplasm, and subsequent proteolytic activation, 5) shunting of zymogens into membrane-
bound compartments that contain active proteases, 6) uptake and processing of secreted 
zymogens by endocytic pathways, and 7) enhanced susceptibility of zymogens to proteolysis 
because of oxidation (Bhatia et al 2005). The first three of these pathways have been studied 
most extensively. Also the intracellular elevation of calcium is believed to be, at least, a 
cofactor in the zymogen activation of AP (Weber and Adler 2003). In AP there are two 
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pathways of the acinar cell death: necrosis and apoptosis (mediated by activation of 
caspases). The conversion of the cell death response to apoptosis has been associated with 
improvement in the severity of AP. (Pandol et al 2007) 
Figure 2. Intra-acinar zymogen activation.
2.6.2 Systemic inflammation 
In the pathogenesis of AP, a local injury and inflammation in the pancreas can proceed to 
systemic inflammation causing SIRS (Figure 3). This is characterized by abnormal body 
temperature, tachycardia, tacypnoe and abnormal leukocyte count (Bone et al 1992).
Normally, the host inflammatory response is confined to the injured interstitial space by 
localization of proinflammatory mediators to the affected area, and by various inhibitors. 
However, if this response is activated in an uncontrolled fashion and disseminated via the 
circulation (becoming systemic), organs distant from the initial insult can be affected, leading 
to multiple organ dysfunction syndrome (MODS). In SIRS many proinflammatory mediators 
(cytokines), nitric oxide (NO) and components of the complement are released. 
Polymorphonuclear neutrophils (PMN) release free radicals and proteolytic enzymes, and 
contribute to the initiation and perpetuation of the inflammatory response. (Norman 1998; 
Granger and Remick 2005) In addition to this, cellular and complement-mediated cytotoxic 
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injury, the sequestration of platelets, leukocytes and erythrocytes in the microvascular 
circulation, cause ischaemic injury. Activation of immunoeffector cells and upregulation of 
proinflammatory cytokines activates also the vascular endothelium, which, in turn, increases 
the expression of cell surface adhesion molecules and produces inflammatory mediators.  
(Figure 8, page 46) (Wilson et al 1998) In systemic inflammation, an excessive 
proinflammatory burst is rapidly followed by an anti-inflammatory reaction that may result in 
immune suppression (Mentula et al 2003), a compensatory anti-inflammatory response 
syndrome (CARS) (Makhija and Kingsnorth 2002).
Figure 3. Inflammatory cascade in acute pancreatitis.
 
2.6.2.1 Inflammatory cells 
The infiltration of inflammatory cells into the pancreas is an early and central event in AP,
and promotes local injury and aggravates systemic complications of the disease. The acinar,
ductal and pancreatic stellate cells play a dynamic role in leukocyte attraction via secretion of 
chemokines and cytokines and expression of adhesion molecules (Bhatia et al 2005). The 
leukocyte movement (adhesion to the blood vessel wall, transmigration through the blood 
vessel wall and infiltration into the parenchyma) is the central event in the pathogenesis of 
AP. The first step in the leukocyte movement is the rolling of leukocytes on the surface of 
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endothelial cells. This phenomen is mediated by selectins, which are a family of cell surface 
molecules on leukocytes and endothelial cells. After rolling, the leukocytes adhere tightly to 
the endothelial cells. This adhesion is mediated by intercellular adhesion molecule (ICAM)-1 
and vascular cell adhesion molecule (VCAM)-1 expressed on endothelial cells, and by 
CD11b-CD18, CD11a-CD18 and integrin alpha4beta1 expressed on neutrophils and 
monocytes. (Repo and Harlan 1999) After adhesion, the leukocytes transmigrate through the 
endothelial barrier into the interstitium, and this is mediated by platelet endothelial cell 
adhesion molecule (PECAM)-1, CD99, junctional adhesion molecules (JAM) and vascular 
endothelial (VE)-cadherin. Finally, the leukocyte movement through the tissues is guided by 
interactions between leukocyte integrins and components of the extracellular matrix (e.g. 
fibronectin, vitronectin, collagen and laminin). (Radi et al 2001; Vonlaufen et al 2007) 
Neutrophils 
Neutrophils are attracted into the pancreas and other tissues by chemokines (e.g. interleukin 
(IL)-8), platelet-activating factor (PAF) and leukotriene B4 (LTB4). Activated neutrophils can 
release myeloperoxidase, proteases (e.g. elastase) and reactive oxygen species (ROS) into 
the interstitium and damage it. (Vonlaufen et al 2007) 
 
Monocytes and macrophages 
The infiltration of monocytes and macrophages in the pathogenesis of AP is similar to the 
infiltration of neutrophils. The activated monocytes and macrophages release ILs-1, -6, -8, 
tumor necrosis factor (TNF)-alpha and ROSs and cause damage. (Vonlaufen et al 2007) 
 
Lymphocytes 
In experimental studies lymphocytes have also been found to infiltrate into pancreatic tissue 
and to release cytokines.  
 
2.6.2.2 Mediators of inflammation 
Proinflammatory mediators believed to participate in the pathogenesis of AP include: TNF-
alpha, IL-1beta, IL-6, PAF, ICAM-1, IL-8, growth-related oncogene-alpha/cytokine-induced 
neutrophil chemoattractant (GRO-alpha/CINC), monocyte chemoattractant protein (MCP)-1, 
and substance P. 
Anti-inflammatory mediators in AP include: IL-10, complement component C5a, soluble TNF 
receptors (sTNFR), IL-1 receptor antagonist (IL-1ra), and neutral endopeptidase (NEP). 
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The expression of these mediators is regulated by transcription factors (e.g. nucler factor 
kappa B, NF-KB) (Makhija and Kingsnorth 2002). (Bhatia et al 2000; Makhija and Kingsnorth 
2002; Bhatia et al 2005; Granger and Remick 2005) 
Tumor necrosis factor-alpha 
TNF-alpha is a polypeptide and predominantly macrophage-derived early phase cytokine 
which interacts via a specific receptor TNFR. TNF is also released by neutrophils and acinar 
cells (Bhatia et al 2005). It has a short plasma half-life, 14-18 min, due to the rapid clearance 
of the liver, gastrointestinal tract and kidney. TNFRs are present on many cells and can be 
released into the circulation as soluble TNFR (sTNFR) by binding of TNF. TNF activates 
neutrophils, upregulates the endothelial adhesion molecules E-selectin and ICAM-1, 
enhances the endothelial expression of tissue factor (TF), increases capillary permeability, 
and has a direct toxic effect on cells. (Conway and Rosenberg 1988; Wilson et al 1998; 
Makhija and Kingsnorth 2002) In severe AP, high levels of TNF have been found in clinical 
and experimental studies (Exley et al 1992; Grewal et al 1994) 
 
Interleukin-1 
IL-1 is an early phase cytokine which is produced by many different cell types, predominantly 
by macrophages, but to a lesser extent also by acinar cells (Bhatia et al 2005). It interacts via 
an IL-1 receptor. It can activate neutrophils and endothelium by upregulation of all classes of 
adhesion molecules. It causes fever, hypotension, increased capillary permeability, and a 
release of other cytokines (Makhija and Kingsnorth 2002). (Wilson et al 1998) 
 
Interleukin-6 
IL-6 is a phosphoglycoprotein and an early phase cytokine which interacts via an IL-6 
receptor. It is produced by monocytes, endothelial cells, smooth muscle cells, fibroblasts and 
periacinar myofibroblasts (Makhija and Kingsnorth 2002; Bhatia et al 2005). It induces 
hepatic synthesis of acute phase proteins (e.g. CRP), stimulates T-cell differentiation and 
promotes proliferation of B-cells. (Wilson et al 1998) 
 
Interleukin-8 
IL-8 is a chemokine which is released mainly by macrophages and endothelial cells. It 
interacts via an IL-8 receptor. It is chemotactic for neutrophils and stimulates their activation. 
(Wilson et al 1998; Makhija and Kingsnorth 2002) 
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Interleukin-10 
IL-10 is an anti-inflammatory cytokine which upregulates IL-1ra and sTNFR production and 
reduces IL-8 and MCP-1 levels (Makhija and Kingsnorth 2002; Bhatia et al 2005). 
Phospholipase A2 
Phospholipase A2 (PLA2) is a group of enzymes which occur in a membrane-associated form 
or in an extracellular (secretory) form. The membrane-associated form generates secondary 
messengers and catalyses the hydrolysis of phospholipids. (Wilson et al 1998) High 
extracellular PLA2 levels have been found in AP patients with SIRS (Hietaranta et al 1999). 
Platelet-activating factor 
PAF is a low molecular weight phospholipid which acts via a specific cell surface receptor. It 
is released by inflammatory cells, such as endothelial cells, macrophages and neutrophils 
(Makhija and Kingsnorth 2002). It induces aggregation of platelets and PMN, systemic 
vasodilatation and increased endothelial permeability. (Wilson et al 1998) PAF is inactivated 
by the enzyme PAF acetylhydrolase (PAF-AH) (Bhatia et al 2005). 
 
2.6.2.3 Complement and CD59 
Complement has a central role in the innate immune system, and is composed of more than 
30 proteins in plasma and on cell membranes. It has three main activities: 1) to defend 
against bacterial infection (opsonization, chemotaxis and activation of leukocytes, and lysis 
of bacteria and cells), 2) to bridge innate and adaptive immunity, and 3) to dispose of 
immune complexes and the products of inflammatory injury and apoptotic cells. (Walport 
2001a)  
 
2.6.2.3.1 Activation of complement 
Complement can be activated by three pathways: 1) the classical, 2) mannose-binding lectin 
(MBL), and 3) alternative pathways (Figure 4). (Walport 2001a; Cole and Morgan 2003) The 
classical pathway begins when antibody binds to a cell surface, and the C1 proteins 
(composing of one C1q, and two C1r and C1s units) C1q unit binds to antibody. After that 
C1r and C1s are activated, and C1s cleaves C4 protein to C4a and C4b, and C2 protein to 
C2a and C2b forming C4bC2a convertase. C4bC2a then cleaves C3 protein to C3a and C3b, 
and C5 protein to C5a and C5b. C5b forms the C5b-C9 complex with proteins C6, C7, C8 
and several C9 proteins; it is the membrane-attack complex (MAC) (Podack and Tschopp 
1984). The lectin-pathway is similar to the classical pathway, and it begins when MBL binds 
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to mannose groups on the bacterial surface, and its mannose-binding lectin-associated 
serine proteases (MASP)-1 and MASP2 activate C2 and C4 proteins. After that the pathway 
is the same as the classical pathway. The alternative pathway is, in minimal extent, activated 
at all times. C3 protein can be hydrolyzed to C3(H2O) and can bind to factor B, which can be 
cleaved to Bb by factor D. This formed C3(H2O)Bb complex can cleave C3 protein to C3a 
and C3b. Factor D cleaves factor B to Bb, which forms the C3bBb convertase with C3b. 
Factor P (properdin) stabilizes C3bBb. This C3bBb convertase is similar to C4bC2a 
convertase, and can, in turn, cleave C3 and C5 proteins. The forming C5b unites with C6-C9 
proteins, composing the MAC. 
Classical pathway                       Mannose-binding lectin               Alternative pathway 
                                                      pathway 
                                                                                                             Activating surface  
Antigen/Antibody complexes         Mannose                  C3(H2O)Bb                    
                                                                                                          
                             C2 + C4 
                                                                                        C3           C3b  
Activated C1                                MBL + MASP 1, 2 
                                                                                                                          fB, fD 
                                                                                                             
                              C4b2a                                                                   C3bBb 
                                                                     C3                                         
                                                                        
                                                                         
                                                                                C3a 
                                                                    C3b  
 
                             C4b2a3b                                                              C3bBbC3b 
                                                                     C5 
                                                                        
                                                                                C5a                                                                      
                                                                    C5b 
                                   C6, C7, C8, C9            
 
                                                                   
                                                                    
                                                                   
 
Figure 4. Complement activation pathways, (MBL=mannose-binding lectin, MASP=mannose-binding 
lectin-associated serine protease, fB=factor B, fD=factor D, MAC=membrane-attack complex). 
 
MAC 
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The main function of MAC is to destroy invading organisms and, possibly, malignant cells by 
comprising a transmembrane channel and forming ultrastructural membrane lesions (Podack 
and Tschopp 1984; Morgan 1999). In the activation of complement, by cleavage of C3 and 
C5, small fragments, i.e. C3a and C5a, are released. They have powerful anaphylactic 
properties (on phagocytic cells, mast cells and basophils) and C5a has also chemotactic 
properties (on leukocytes) (Morgan 1999; Cole and Morgan 2003). In the activation of 
complement, also C3b and C4b are released, and they can opsonize pathogens for 
phagocytosis (Cole and Morgan 2003).     
When tissue injury occurs, complement can be activated through immune complexes, and 
ischemia and reperfusion, which expose mitochondrial proteins and phospholipids 
(neoantigens) (Barrington et al 2001). Necrotic cells also lack the regulatory proteins, which 
normally inhibit complement binding. The activated complement can cause damage through 
MAC and by activating leukocytes bearing complement receptors for C3b and C4b. It can 
also amplify the tissue injury by activating inflammatory cells via anaphylatoxins C5a and 
C3a. (Walport 2001b; Cole and Morgan 2003) MAC has also proinflammatory properties on 
nucleated host cells and endothelial cells by inducing the release of inflammatory mediators, 
secretion of cytokines, degranulation and proliferation of these cells (Morgan 1999; Cole and 
Morgan 2003). In an in vitro study it was shown that coagulation factors Xa and XIa, plasmin 
and thrombin can cleave C3 and C5 to generate C3a and C5a (Amara et al 2008). Products 
of complement activation have been found to collaborate with the adaptive immune system 
to enhance responses to antigens (Cole and Morgan 2003). Complement has also anti-
inflammatory properties; it clears immune complexes from tissues, and binds to apoptotic 
cells helping to eliminate them (Walport 2001b). 
 
2.6.2.3.2 Regulation of complement 
Complement is regulated by many mechanisms which are balanced so that the activation of 
complement takes place on the surface of invading microorganisms, and the deposition of 
complement on normal cells is limited. Deficiencies of complement or its regulator proteins, 
as well as disturbances in the complement regulator mechanisms can cause many diseases, 
e.g.  susceptibility to pyogenic infections, hemolytic-uremic syndrome, glomerulonephritis, 
and systemic lupus erythematosus. (Walport 2001a) 
Several proteins in the plasma and on cell membranes downregulate the activation of 
complement (Table 1). In the plasma, C1 inhibitor (C1inh) inhibits the function of C1, and 
C4b binding protein (C4bp), and factors H and I inhibit C3C5 convertase. On cell 
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membranes, the decay accelerating factor (DAF), membrane cofactor protein (MCP), and 
complement receptor (CR)-1 inhibit also C3C5 convertase, and CD59 inhibits C5b-C9 
complex (Barrington et al 2001). (Morgan 1999) The function of MAC-controlling proteins is 
to restrict lysis to target membranes and to prevent lysis of innocent bystander or host cells. 
These proteins include also C5b-7 inhibitors and S-protein, which inhibits C9 polymerization 
and channel formation. (Podack and Tschopp 1984) Nucleated cells (e.g. neutrophils) can 
also remove MACs from the cell membrane by Ca-dependent shedding or endocytosis. C5a 
and C3a are inactivated by a plasma enzyme called carboxypeptidase N (CPN). (Morgan 
1999)  
 
Table 1. Complement regulatory proteins, (C1inh=C1 inhibitor, CPN=carboxypeptidase N, 
MCP=membrane cofactor protein, DAF=decay-accelerating factor, CR1=complement receptor 1).  
Molecule Target or function 
 Plasma  
    C1inh C1 and C4Bb 
    factor H C3/C5 convertase 
    factor I C3/C5 convertase 
    C5b-C7 inhibitors inhibit channel formation of MAC 
    S-protein inhibit channel formation of MAC 
    CPN C3a and C5a 
 Membrane  
    MCP C3/C5 convertase 
    DAF C3/C5 convertase 
    CR1 C3/C5 convertase 
    CD59 C5b-C9 complex 
 
 
2.6.2.3.3 Complement and acute pancreatitis 
Pancreatic proteases (trypsin) can activate complement; this has been shown in AP (Foulis 
et al 1982; Whicher et al 1982; Acioli et al 1997; Hartwig et al 2001). In sepsis, trauma and 
AP complement activation has been found to be associated with the development of 
pulmonary damage, ARDS (Jacob and Hammerschmidt 1982; Duchateau et al 1984). 
High plasma levels of C3a and high peritoneal fluid levels of C3a, C5a and C5b-C9 complex 
have been found in AP patients (Bengtsson et al 1990), and high plasma C3a, C5a and C5b-
C9 levels in patients with severe AP (Roxvall et al 1990). When AP patients were treated 
intraperitoneally with protease inhibitor (aprotinin) the C3a levels were lower and the C1INH 
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levels higher than in control patients (Berling and Ohlsson 1996). In a human study C3 
catabolism was increased in AP patients and a falling level of C3 was associated with a fatal 
outcome (Foulis et al 1982). In one clinical study, high levels of C3a and C5b-C9 were 
observed to predict severe AP (Gloor et al 2003). In a clinical study, high levels of 
complement inhibitor protein (C1INH and factor H) were found, but there was no significant 
association with severity of AP (Whicher et al 1982). Children with severe AP and 
complement activation after allogeneic hematopoietic stem cell transplantation were treated 
with C1 esterase inhibitor, which contributed to rapid clinical stabilization (Schneider et al 
1999). An experimental AP study revealed that trypsin-generated complement activation 
takes part in the upregulation of adhesion molecule Mac-1 and in the down-regulation of L-
selectin on neutrophils (Hartwig et al 2001). In C5-deficient mice, edema formation in AP was 
decreased compared to C5-sufficient mice (Merriam et al 1997). 
 
2.6.2.3.4 CD59                  
CD59 is a 20 kDa cell membrane protein which is expressed on all circulating cells, 
endothelia, epithelia, and in most organs (Meri et al 1996). It is linked to the membrane by a 
glycosyl phosphatidylinositol (GPI) anchor and can be removed from cells by 
phosphatidylinositol-specific phospholipase C (PIPLC). Urine, seminal plasma, cerebrospinal 
fluid, amniotic fluid and breast milk also contain fluid-phase forms (lacking the GPI anchor) of 
CD59, i.e. the soluble CD59. These isoforms display specific binding activity towards C5b-
C9. However, because of the absent phospholipid tail, they have limited ability to inhibit MAC 
on cell membranes. (Morgan 1999) CD59 can be shed from epithelial cells either in the form 
of small membrane vesicles, or after cleavage by phospholipase C or D. (Meri et al 1996) 
CD59 binds to C8 and C9, and inhibits the forming of MAC and the transmembrane channel. 
It has been shown to act as an adhesion molecule for T cells, and it has also been proposed 
to have a role in cell activation (Wang et al 2002). (Morgan 1999) 
In humans CD59 deficiency, due to a somatic gene mutation, is known. It causes a disease 
called paroxysmal nocturnal hemoglobinuria (PNH). In this disease erythrocytes and platelets 
lack CD59 and are highly sensitive to autologous complement-mediated lysis and activation, 
resulting in hemolytic anemia and thrombosis. (Baalasubramanian et al 2004) High plasma 
CD59 levels have been found in patients with acute myocardial infarction (Vakeva et al 
2000). CRP-induced upregulation of complement inhibitor proteins (DAF, MCP and CD59) 
was found on human endothelial cells, and these proteins were functionally effective in 
reducing complement-mediated cell lysis (Li et al 2004). In an animal rheumathoid arthritis 
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model, recombinant soluble CD59 was found to suppress the disease markedly (Fraser et al 
2003).  
 
2.6.2.4 High mobility group box 1 protein, a receptor for advanced glycation 
end products and a soluble form of receptor for advanced glycation end 
products  
 
High mobility group box 1 protein 
High mobility group box 1 (HMGB1) is a 30 kDa nuclear and cytosolic protein which is 
produced by nearly all cell types (Limana et al 2005). It is composed of three domains: two 
homologous DNA-binding motifs, A box and B box, and a negatively charged C terminus 
(Yang et al 2005). In inflammation, it is produced by activated macrophages, and can be 
released actively (after endotoxin or endogenous cytokine stimulation) by these cells, or 
passively by necrotic cells. (Wang et al 2004a) 
HMGB1 can bind to the receptor for advanced glycation end products (RAGE) (Rouhiainen 
et al 2004) and Toll-like receptors (TLRs) 2 and 4 (Li et al 2006; Ito et al 2007). 
HMGB1 is a cytokine mediator of inflammation and, in particularly, a late mediator of sepsis 
(it is secreted 20 h post-stimulation) (Wang et al 2004a; Mantell et al 2006). It acts also as a 
transcription cofactor and a growth factor (Bustin 1999; Limana et al 2005). It can activate 
macrophages, monocytes and neutrophils to release proinflammatory cytokines, and 
endothelial cells to upregulate adhesion molecules. On epithelial cells it stimulates barrier 
failure, and on adherent cells migration (Mitola et al 2006). HMGB1 also mediates 
transendothelial migration of monocytes (Rouhiainen et al 2004).  
Increased serum levels of HMGB1 have been found in patients with disseminated 
intravascular coagulation (DIC) (Hatada et al 2005), hemorrhage (Kim et al 2005), sepsis 
(Eriksson 2005; Sunden-Cullberg et al 2006; Ito et al 2007) and acute lung injury (Ueno et al 
2004). In experimental sepsis studies, high levels of HMGB1 have been found; the 
administration of recombinant HMGB1 has induced symptoms of sepsis, and inhibition of 
HMGB1 has prevented endotoxin- and bacteremia-induced MOF (Yang et al 2005; Mantell et 
al 2006). In an animal model of thrombin-induced DIC, HMGB1 induced TF expression on 
monocytes and inhibited protein C (PC) activation, mediated by the thrombin-
thrombomodulin (TM) complex (Ito et al 2007). TM has been shown to bind to HMGB1 and 
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prevent its proinflammatory effects (Abeyama et al 2005). In an animal study, HMGB1 
pretreatment was found to decrease liver damage after ischemia/reperfusion (Izuishi et al 
2006). The plasma levels of HMGB1 in patients with DIC and organ failure were significantly 
higher than in patients with DIC but without organ failure, and also higher in non-survivors 
than in survivors (Hatada et al 2005). In one clinical study, elevated serum HMGB1 levels 
were found in AP patients (Yasuda et al 2006). 
 
Figure 5. Intra- and extracellular functions of HMGB1, (TF=tissue factor, PC=protein C, 
TM=thrombomodulin).
 
Receptor for advanced glycation end products and soluble form of receptor for 
advanced glycation end products
RAGE is a member of the immunoglobulin superfamily, and is expressed on endothelium, 
neurons, vascular smooth muscle cells and on mononuclear phagocytes (Abeyama et al 
2005; Li et al 2006).
RAGE have many ligands, e.g. advanced glycation end products (AGEs), HMGB1, members 
of the S100 family and amyloid peptide. The binding of a ligand activates the NF-KB
signaling and the mitogen-activated protein kinase (MAPK) pathways (Wang et al 2004a).
This ligand binding induces cell migration, cell invasion, tumor growth and metastasis (Mitola 
et al 2006).
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A soluble form of RAGE (sRAGE) is present in the circulation (Yonekura et al 2003); it 
comprises the extracellular domain of RAGE (Bierhaus et al 2005), and preserves its original 
ligand-binding capacity (Schmidt et al 2000). The circulating pool of sRAGE consists of a 
splice variant, named endogenous secretory RAGE (esRAGE) and proteolytically cleaved 
forms of RAGE (Hudson et al 2005). Elevated levels of sRAGE have been found in disorders 
such as end-stage renal disease (Kalousova et al 2007) and acute lung injury (Uchida et al 
2006), and reduced levels have been found in rheumathoid arthritis (Pullerits et al 2005), 
Alzheimer’s disease (Emanuele et al 2005) and essential hypertension (Geroldi et al 2005). 
 
2.6.3 Coagulation and hemostatic factors 
Hemostasis involves vessel wall and endothelial cells, soluble plasma proteins (coagulation 
proteins and their regulators), cellular components within the vessel lumen (red blood cells, 
platelets and leukocytes), and microparticles derived from platelets and leukocytes (Furie 
and Furie 2007). It is a physiologic process which controls the blood fluidity and, at the same 
time, has the capacity to produce a hemostatic plug outside a damaged blood vessel. 
Thrombosis refers to the same event inside the vessel lumen, and consists of platelet 
accumulation, adhesion, activation and aggregation, as well as tissue-factor-initiated 
thrombin generation and fibrin formation (Furie and Furie 2007). Blood coagulation, a precise 
and balanced thrombin generation at sites of vascular damage, is induced by adherent 
platelets (Butenas and Mann 2002). In healthy persons, the hemostatic process is counter-
balanced by a system of anticoagulant mechanisms which ensure that the hemostatic effect 
is regulated, and does not extend inappropriately. Normally these anticoagulant factors are 
slightly dominating. (Dahlback 2000) In pathologic states (e.g. systemic inflammation), 
however, these hemostatic events can escape the control mechanisms, and this leads to 
thrombosis. 
 
2.6.3.1 Models of coagulation 
Previously, the ‘Waterfall’ or ‘Cascade’ model of coagulation divided it into extrinsic and 
intrinsic pathways, which united at the level of factor X, forming a common pathway (Figure 
6) (Davie and Ratnoff 1964; Macfarlane 1964). According to this model, blood coagulation 
involves a wide series of coordinated and calcium-dependent conversions of proenzymes to 
the respective serine proteases, culminating finally in the conversion of prothrombin into 
thrombin (Dahlback 2000). In the extrinsic pathway after vascular damage, TF is exposed to 
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the circulation and binds to and activates factor VII to FVIIa. The TF-FVIIa complex activates 
both FIX and FX to FIXa and FXa. In the intrinsic pathway on negatively charged surfaces, 
contact activation of factor XII occurs in the presence of prekallikrein and high molecular 
weight kininogen. The FXIIa then activates factor XI to XIa, which in turn activates factor IX 
to FIXa. The FIXa further activates factor X with factor VIIIa. In the common pathway, FXa 
forms a prothrombinase complex with factor Va, which then leads to the conversion of 
prothrombin to thrombin. Thrombin further converts fibrinogen to fibrin. Within this cascade 
model, the contribution of primary hemostasis by platelets was considered to be an 
independent mechanism (Adams and Bird 2009). Prothrombin time (PT) measures the 
extrinsic pathway, and activated partial thromboplastin time (aPTT) measures the intrinsic 
pathway (Tanaka et al 2009). 
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Figure 6. The cascade model of coagulation, (TF=tissue factor). 
 
The cascade model was replaced, almost a decade later, by a cell-based model of 
coagulation (Figure 7) (Hoffman and Monroe 2001). In this model, coagulation is believed to 
occur in three overlapping stages: 1) initiation, 2) amplification, and 3) propagation (Hoffman 
and Monroe 2001). In the initiation phase, TF is exposed to coagulation factors either by TF-
bearing cells or by damage to endothelium. TF forms a complex with factor VIIa on the 
phospholipid surface of the cell membrane, after which, this complex activates factors IX and 
X. The activated factor X forms a complex with Va, and this complex further converts 
prothrombin to thrombin. In the amplification phase, platelets and cofactors are activated to 
generate more thrombin, which, in turn, activates more platelets and cofactors enhancing the 
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thrombin-generating potential. Both TF-VIIa and FIXa-FVIIIa complexes activate FX, leading 
to thrombin generation. In the propagation phase, large amounts of thrombin are generated 
on the surface of the platelets. This causes a thrombin burst, which further generates fibrin 
from fibrinogen. The forming thrombin also activates factor XIII and thrombin-activatable 
fibrinolysis inhibitor (TAFI). The factor XIIIa cross-links with fibrin strands to form a stable 
fibrin network, and the TAFI protects the forming clot from plasmin-mediated fibrinolysis. 
(Dahlback 2000; Butenas and Mann 2002) 
Figure 7. The cell-based model of coagulation.
There is a basic difference between the cascade model and the cell-based model. In the 
cascade model, the coagulation factors are thought to control and direct coagulation on the 
cell surfaces, whereas in the cell-based model the cells are thought to regulate the 
coagulation process by different cell-surface receptors for coagulant factors (Hoffman and 
Monroe 2001). Furthermore, in the cell-based model also the activated platelets seem to 
have a more important role, and the coagulation is believed to occur by the overlapping of 
different phases, rather than in a series of events, as implied in the cascade model.  
2.6.3.2 Regulation of coagulation 
Regulation of coagulation occurs at each level of the pathway, either by enzyme inhibition or 
by modulation of the activity of the cofactors (Vine 2009). The natural anticoagulant systems 
consist of tissue factor pathway inhibitor (TFPI), antithrombin (AT), protein C (PC) pathway, 
and protein S (PS).
37 
 
TF is regulated by TFPI (Morrissey 2001), which binds to and inhibits the FXa and the TF-
FVIIa complex.  
AT binds to and inhibits primarily thrombin, but also factors Xa and IXa (Esmon 2004a; Lippi 
et al 2009). 
PC is activated by thrombin bound to TM, becoming activated protein C (APC), which 
proteolytically cleaves and inhibits factors Va and VIIIa. PS works as a cofactor for APC. 
(Esmon 2000; Butenas and Mann 2002) 
 
2.6.3.3 Disseminated intravascular coagulation 
DIC is an acquired syndrome characterized by systemic activation of coagulation, which 
leads to intravascular deposition of fibrin and microvascular thrombosis (Muller-Berghaus et 
al 1999). Vascular thrombosis, in turn, can contribute to OF. At the same time, the 
accelerated consumption of platelets and coagulation factors can induce bleeding. The 
common clinical conditions that are associated with DIC are sepsis, trauma, malignancy, 
obstetrical complications, severe toxic or immunological reactions, severe hepatic failure, 
vascular abnormalities, and organ destruction e.g. severe AP. (Taylor et al 2001) The 
definition of DIC includes overt and non-overt DIC; the former means a stressed, but 
decompensated hemostatic system, and the latter a stressed but compensated hemostatic 
system (Taylor et al 2001). The frequency of the occurrence of DIC in different diseases 
varies considerably, in sepsis overt DIC may occur in 30-50 % and in trauma in 50-70 % of 
cases. The development of DIC increases the risk of death in the underlying conditions. (Levi 
and Ten Cate 1999)   
The central features in the pathogenesis of DIC include increased formation of fibrin, 
suppression of the natural anticoagulant systems, and impairment of fibrinolysis. The 
systemic formation of fibrin is caused by TF-induced and increased thrombin generation. All 
the natural anticoagulant mechanisms (AT, PC and TFPI) are suppressed in the course of 
DIC due to the ongoing coagulation, increased levels of proinflammatory mediators (Conway 
and Rosenberg 1988; Taylor et al 1991), impaired synthesis or their insufficient regulatory 
capacity (Creasey et al 1993; Mesters et al 1996; Kessler et al 1997). The inhibition of the 
fibrinolytic system is caused by increased plasma levels of plasminogen-activator inhibitor 
(PAI)-1. (Levi and Ten Cate 1999) 
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The diagnosis of DIC is based on a combination of test results and a clinical DIC-associated 
condition. The scientific subcommittee on DIC of the International Society on Thrombosis 
and Haemostasis (ISTH) has created a diagnostic scoring system for overt DIC; it is a 5-step 
algorithm giving a DIC score (Table 2). A score of 5 or more is compatible with overt DIC, 
whereas a score of less than 5 may be indicative (but is not affirmative) for non-overt DIC. 
(Taylor et al 2001) 
In the management of DIC, treatment of the underlying disorder is of crucial importance. 
However, other supportive measures may be necessary (e.g. transfusion of red blood cells 
and plasma, or administration of heparin) in the case of severe bleeding or thrombosis.   
 
Table 2. Diagnostic algorithm for the diagnosis of overt DIC according to the Scientific Subcommittee 
on DIC of the International Society on Thrombosis and Haemostasis. 
 
1) Risk assessment: Does the patient have an underlying disorder known to be associated with 
overt DIC (e.g. sepsis / severe infection, trauma, organ destruction, malignancy, obstetrical 
calamities, vascular abnormalities, severe hepatic failure, severe toxic or immunologic 
reactions)? 
      If yes: proceed ; If no: do not use this algorithm 
2) Order global coagulation tests (platelet count, prothrombin time, fibrinogen, soluble fibrin 
monomers or fibrin degradation products) 
 
3) Score global coagulation test results 
- platelet count (>100=0; <100=1; <50=2) 
- elevated fibrin-related marker (no increase=0; moderate increase=2; strong 
increase=3) 
- prolonged prothrombin time (<3 sec.=0; >3 sec. but <6 sec.=1; >6 sec.=2) 
- fibrinogen level (>1.0 g/l=0; <1.0 g/l=1) 
 
4) Calculate score 
 
5) If >/= 5: compatible with overt DIC; repeat scoring daily 
      If < 5: suggestive (not affirmative) for non-overt DIC; repeat next 1-2 days 
 
 
2.6.3.4 Coagulation and inflammation 
In critically ill patients, both the inflammatory system and coagulation are activated. There is 
extensive cross-talk between these two systems, whereby inflammation leads to activation of 
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coagulation, and coagulation affects inflammatory activity. The key factor in linking these two 
systems is TF, which is expressed by monocytes after cytokine (IL-6) stimulation, and 
exposed to blood after endothelial damage (Esmon 1999; Levi and van der Poll 2008). The 
activation of coagulation by TF leads to thrombin generation and fibrin formation. Thrombin 
and proinflammatory cytokines (PAF) activate platelets (Dahlback 2000), and this further 
enhances TF expression (Mackman 2004). Inflammatory mediators also increase platelet 
production, and the newly formed platelets appear to be more thrombogenic (Esmon 2005b). 
Simultaneously, the function of natural anticoagulant systems (in particularly PC and AT) is 
impaired by proinflammatory mediators, and the ongoing thrombin generation leads to their 
consumption, and their levels thus decrease (Esmon 2000; Levi and van der Poll 2008). In 
experimental studies, TNF-alpha, IL-1 and endotoxin are found to down-regulate TM and 
endothelial protein C receptor (EPCR) expression (Esmon 1999). The classical complement 
pathway regulator protein C4bp binds PS and diminishes its cofactor effect on PC (Vine 
2009). Complement activation generates the C5b9 complex, which can cause exposure of 
phosphatidylserine on the surface of the cells, where it can take part in the initiation and 
amplification of the coagulation cascade (Esmon 2004a). 
Coagulation can also greatly modulate inflammatory activity. The binding of coagulation 
proteases, e.g. thrombin, TF, and factors VIIa and Xa, can activate protease-activated 
receptors (PAR 1-4). These receptors have a critical role in inflammation and coagulation. 
(Coughlin 2000) For example, activation of PARs triggers platelet aggregation and causes 
endothelium to express numerous adhesion molecules on its surface (Vine 2009). The 
natural anticoagulant systems also possess many anti-inflammatory properties (Feistritzer 
and Wiedermann 2007; Levi and van der Poll 2008). EPCR can be shed from endothelium 
by thrombin and inflammatory mediators, and bind to activated neutrophils, inhibiting their 
extravasation (Esmon 2004a). Thrombin activates also TAFI, which is an inhibitor of the 
complement anaphylatoxin C5a, and bradykinin (Esmon 2005a). TM can bind and neutralize 
HMGB1, which is a late stage mediator of systemic inflammation (Abeyama et al 2005; 
Esmon 2005b). 
 
2.6.3.5 Coagulation disturbances and acute pancreatitis 
Coagulative disorders (mainly consumptive coagulopathy and increased fibrinolysis (Lasson 
and Ohlsson 1986a; Lasson and Ohlsson 1986b)) are known to occur in severe AP, and they 
are related to its severity and to OF. In the pathogenesis of pancreatic necrosis, the 
pancreatic perfusion and hypoxia seem to play an important role. There is accumulating 
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evidence that microvascular disturbances (vasoconstriction, shunting, increased 
permeability, inadequate perfusion, and increased blood viscosity and coagulation) are 
significant events in the progression of AP. Reduced tissue blood flow in AP is related to its 
severity. (Cuthbertson and Christophi 2006) In severe AP, large vessel hemodynamic 
changes are common, and also markers for hypovolemia (hemoconcentration, tachycardia, 
oliguria, azotemia and hypotension) are often observed in the patients on admission to 
hospital (Pandol et al 2007). 
The levels of DIC parameters (low levels of platelets and AT, and high levels of D-dimer) and 
thrombin-antithrombin complex at admission have been found to be associated with severity 
and prognosis of AP (Maeda et al 2006). D-dimer levels about four-fold the upper reference 
limit have been shown to be a sign of severe AP (Salomone et al 2003). The study group of 
Maeda also found that low PC levels are related to the severity and prognosis of AP 
(Radenkovic et al 2006). In severe AP, nonsurvivors have been found to have lower PC and 
AT levels, and higher D-dimer and plasminogen activator inhibitor (PAI)-1 levels than 
survivors (Radenkovic et al 2004). In one clinical study, the use of recombinant FVIIa for 
bleeding in pancreatitis showed an improvement in the coagulation parameters, and there 
were no thromboembolic events (Laffan et al 2005). In Japanese experimental and clinical 
studies, the continuous regional arterial infusion of antiproteases has been shown to diminish 
pancreatic necrosis and reduce mortality in severe AP (Takeda 2007). In an animal study, 
pretreatment with anti-FVIIa reduced IL-6 and macrophage inflammatory protein-2 levels in 
AP (Andersson et al 2007). 
 
2.6.3.6 Protein C and activated protein C 
PC is a vitamin-K-dependent serine protease zymogen, which circulates in plasma (Griffin et 
al 2006). It is activated by thrombin bound to TM on the endothelial surface, becoming APC, 
which proteolytically cleaves and inhibits factors Va and VIIIa, and further dampens thrombin 
generation (Esmon 2000). APC can stimulate fibrinolysis by forming a complex with PAI-1 
that leads to inactivation of this fibrinolysis inhibitor (Esmon 2004a). APC can dampen NF-KB 
signaling in monocytes, decrease the ability of inflammatory mediators to induce TF 
formation in leukocytes (Esmon 2004b), inhibit neutrophil adhesion to endothelium, and 
decrease endothelial cell apoptosis (Esmon 2005a; Mosnier et al 2007). PC and APC can 
bind to EPCR, which enhances their activity. This APC-EPCR complex does not appear to 
have anticoagulant activity (Esmon 2004a). PS works as a cofactor for APC in inhibiting FVa 
and FVIIIa. EPCR can be shed from endothelium by thrombin and inflammatory mediators, 
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and can bind to activated neutrophils inhibiting their extravasation. It can also undergo 
translocation from the plasma membrane to the nucleus, and redirect gene expression. It can 
simultaneously carry APC to the nucleus. (Esmon 2004a) APC is inactivated by alpha1-
antitrypsin, PC inhibitor and alpha2-macroglobulin (Esmon 2000).  
Hereditary PC and PS deficiency (Esmon 2000), and APC resistance (factor V Leiden) 
(Mosnier et al 2007) increase the risk of venous thrombosis. Low levels of PC or APC have 
been found in the plasma of patients with post-infection ischemic stroke (Griffin et al 2006), 
sepsis (Fourrier et al 1992; Lorente et al 1993), and acute lung injury (Ware et al 2003). High 
plasma levels of APC have been found to associate with a lower risk of ischemic stroke 
(Griffin et al 2006). In an experimental study, a significant decrease in PC levels was found at 
the onset of severe AP (Ottesen et al 1999). In experimental animal studies, infusion of APC 
or recombinant APC has been found to have a neuroprotective effect (Griffin et al 2006), to 
decrease serum markers of inflammation (Yamanel et al 2005), to increase EPCR and TM 
expression in pancreatic tissue in severe AP (Ping et al 2009), and to improve survival in 
severe AP (Alsfasser et al 2006). In a clinical study, recombinant APC (drotrecogin alfa) was 
found to reduce mortality in severe sepsis patients (Bernard et al 2001). 
 
2.6.3.7 Prothrombin, prothrombin fragments F1+2 and thrombin 
Prothrombin is a vitamin-K-dependent serine protease. It is produced in the liver, and at 
much lower levels in other tissues, such as the brain, diaphragm, kidney, spleen and 
intestine. (Licari and Kovacic 2009) Prothrombinase complex cleaves prothrombin to 
thrombin, and at the same time prothrombin fragments (F1+2) are released. F1+2 are used 
as an in vivo thrombin generation marker. Thrombin plays an essential role in both pro- and 
anticoagulant processes. It converts fibrinogen to fibrin, and activates FXI by generating in 
this way FIXa. It also activates FXIII, TAFI and other cofactors, and stimulates platelets via 
PARs (Dahlback 2000; Mackman 2004). Thrombin bound to TM activates PC, and in this 
way enhances the anticoagulant system (Esmon 2000). Thrombin is inhibited by AT and PC 
inhibitor (Esmon 2000).  
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2.6.3.8 Tissue factor and tissue factor pathway inhibitor 
 
Tissue factor 
TF is a transmembrane protein consisting of three domains: an extracellular, transmembrane 
and cytoplasmic domain (Spicer et al 1987). The extracellular and transmembrane domains 
take part in forming complex with FVIIa, and in activating FVII, FIX and FX (Martin et al 1995; 
Kittur et al 2004). Additionally, the cytoplasmic domain is involved in signal transduction (Ott 
et al 2005). TF is expressed in the vascular adventitia, in organ capsules, in myocardial cells 
(Drake et al 1989; Fleck et al 1990) and astrocytes (Eddleston et al 1993). It is found in 
epidermis, lungs, placenta and in the central nervous system (Drake et al 1989; Fleck et al 
1990). Macrophages and monocyte express TF after inflammatory cytokine stimulation 
(Esmon 1999; Nijziel et al 2001; Bouchard and Tracy 2003) and tumor cells express it (Rak 
et al 2009). There are controversial reports suggesting that also platelets and granulocytes 
might express TF when resting or after stimulation (Eilertsen and Osterud 2004; Butenas et 
al 2009), and that microparticles derived from these cells might bear TF (Furie and Furie 
2007). A soluble form of TF (spliced TF) circulating in blood has also been identified 
(Bogdanov et al 2003). The TF-factor VIIa complex has two plasma inhibitors: TFPI and AT 
(Morrissey 2001). 
Normally, in a healthy person, physiologically active TF is not expressed by cells that are in 
contact with blood (Butenas and Mann 2004). After damage to the endothelial wall, however, 
subendothelial TF is exposed to blood and can bind plasma factor VIIa, forming TF-factor 
VIIa complex. This complex is known to initiate blood coagulation by activating factors IX and 
X, leading ultimately to thrombin generation and fibrin formation. The role of soluble TF is still 
unknown, and there are controversial findings regarding its procoagulant qualities (Eilertsen 
and Osterud 2004; Butenas et al 2009). TF is also thought to be a central link between the 
coagulation and inflammation pathways, and this function is mainly performed through the 
PARs (1-4) (Pawlinski and Mackman 2004). 
High levels of TF have been found in plasma from patients with sepsis, trauma (Gando et al 
1998), acute coronary syndromes (Soejima et al 1996; Suefuji et al 1997) and DIC (Shimura 
et al 1997). In many malignancies, TF has been proved to influence metastasis, tumor 
growth and angiogenesis (Rak et al 2006; Rak et al 2009). There are also animal and human 
studies indicating that TF is a therapeutic target, mainly by different inhibitors (Eilertsen and 
Osterud 2004). 
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In one study, the TF levels of AP patients were significantly higher than those of healthy 
volunteers, but there was no statistically significant difference in the TF levels between the 
severity groups of patients (Sawa et al 2006).  
 
Tissue factor pathway inhibitor 
TFPI is a plasma serine protease inhibitor and consists of three Kunitz-type domains (Girard 
et al 1989). The first domain binds to FVIIa, the second one binds to and inhibits FXa (Girard 
et al 1989), and the third domain may influence the association of TFPI with lipoproteins 
(Broze et al 1990) and cell surfaces (Piro and Broze 2004). TFPI is produced by the liver, 
monocytes, macrophages and endothelial cells (Lwaleed and Bass 2006). Intravascular TFPI 
is found in three different pools: the first one is in the circulation, the second is found in the 
cytoplasm of platelets, and the third, and largest, pool is bound to the endothelium 
(DelGiudice and White 2009). TFPI exits in plasma both as a full-length molecule, and 
variably as carboxy-terminal truncated forms (Warshawsky et al 1995). In plasma, 
approximately 80% of TFPI circulates in complex with lipoproteins (Lwaleed and Bass 2006) 
and about 5-20% of TFPI circulates free (Lindahl et al 1992) containing both full-length and 
C-terminal truncated forms (Broze et al 1994). Heparin and glycosaminoglycans induce free 
TFPI released from the vessel wall (Sandset et al 1988).  
TFPI binds and inhibits factor Xa and TF-factor VII/VIIa complex. The full-length TFPI 
molecule is more efficient in inhibiting TF-FVIIa activity than the C-terminal truncated form 
(Warshawsky et al 1995). The free TFPI has a more potent anticoagulant effect than the 
lipoprotein-associated TFPI (Lindahl et al 1992). 
The role of TF and TFPI has been studied in various models of sepsis. In most of these 
studies the main aim has been to inhibit TF, for example by antibodies or by using 
recombinant TFPI (rTFPI). There are also human studies in which rTFPI has been used with 
controversial results, regarding mortality and side effects (Pawlinski and Mackman 2004; 
DelGiudice and White 2009). High levels of TFPI have been found in the plasma of patients 
with deep venous thrombosis (Sidelmann et al 2008), acute myocardial infarction (Brodin et 
al 2004), hyperthyroidism (Ozcan et al 2003), pregnancy hypertension (Abdel Gader et al 
2006), and high factor XI-TFPI complex levels in patients with solid malignant tumors 
(Iversen et al 2002). Low plasma levels of TFPI have been found to increase the risk of 
venous thrombosis (Dahm et al 2003). 
44 
 
One study has investigated the TFPI levels in AP patients (Yasuda et al 2009). The levels 
were significantly higher than those in healthy volunteers, and there was a significant 
difference in the TFPI levels between the severity groups of the patients. However, there was 
no significant difference in the TFPI levels between the survivors and non-survivors.  
 
2.6.3.9 Platelets 
In the thrombus formation, the platelet plug intertwines with the fibrin meshwork (Furie and 
Furie 2007), and the initial adhesion of platelets at the sites of vascular injury is mediated by 
von Willebrand factor (VWF) and fibrinogen (Furie and Furie 2007; Lippi et al 2009). They 
have an active and necessary role in the amplification and propagation phases of 
coagulation, as they provide a localizing surface in the direct proximity of the damaged area, 
in which most of the elements needed for coagulation are situated. In addition they provide a 
negatively charged phospholipid surface on which reactions can occur. (Esmon 1999; Furie 
and Furie 2007) Platelets are activated by exposed collagen after vascular damage, and by 
thrombin generated at the site of vascular damage ((Furie and Furie 2007). When activated, 
they are able to generate ROSs, NO and proinflammatory mediators (Uhlmann et al 2008). 
In clinical studies, platelets have been shown to be activated, their indices have been 
elevated, and functional changes have occurred in AP (Kakafika et al 2007). In patients with 
severe AP, low plasma levels of platelets were found, and they were prognostic for poor 
outcome (Maeda et al 2006).  
 
2.6.3.10 Protein S 
PS is a plasma glycoprotein circulating in two forms: a free form (40%) and a complex form 
bound to complement protein C4b binding protein (60%). Only the free form retains 
anticoagulant activity. (Taylor et al 1991) In the anticoagulant pathway, PS works as a 
cofactor to PC, inactivating factors Va and VIIIa. (Lippi et al 2009) 
 
2.6.3.11 Antithrombin  
AT is a plasma serine protease inhibitor and a glycoprotein which consists of three beta-
sheets, nine alpha-helices and a reactive centre loop. It exists in two isoforms, alpha (90%) 
and beta (10%). (Roemisch et al 2002; Quinsey et al 2004) The beta-isoform appears to be 
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enriched in the vessel wall (Roemisch et al 2002) and has greater affinity for heparin 
(Wiedermann 2006). AT is synthesized in the liver (Quinsey et al 2004). 
AT is a natural anticoagulant and has also anti-inflammatory properties. It binds irreversibly 
and primarily to factors Xa, IXa and thrombin. However, it has also minor inhibitory effects on 
factors XIIa, XIa, and the TF-factor VIIa complex (Lippi et al 2009). (Esmon 2004a) AT 
inhibits also plasmin and trypsin (Abildgaard 2007). The anticoagulant activity of AT is 
significantly enhanced by heparin (Esmon 2004a; Tanaka et al 2009) and vessel wall-
associated glycosaminoglycans (GAG) (Roemisch et al 2002). The anti-inflammatory 
properties of AT can be either indirect or direct. The indirect effects are induced by AT’s 
anticoagulant actions; by binding thrombin or factor Xa, AT can block their proinflammatory 
actions at the same time.  AT has direct anti-inflammatory properties by inducing prostacyclin 
release from endothelial cells, by reducing leukocyte-endothelium interactions (leukocyte 
rolling and adhesion), by inhibiting cellular signaling and by modulating cellular receptor 
expression (Mammen 1998; Esmon 2005b). These actions are probably mediated by the 
binding of AT to cell-surface GAGs and syndecan-4. Heparin is known to block the anti-
inflammatory actions of AT by preventing its binding to GAGs. (Wiedermann and Romisch 
2002; Roemisch et al 2002) 
Congenital AT deficiencies (both quantitative and qualitative) increase the risk for venous 
thrombosis (Maclean and Tait 2007). Low plasma levels of AT have been found in patients 
with sepsis (Fourrier et al 1992; Lorente et al 1993; Roemisch et al 2002; Wiedermann 2006) 
and severe AP (Maeda et al 2006). In patients with severe AP, low AT levels (cutoff value < 
69%) at admission were found to predict a poor outcome (Maeda et al 2006). In an 
experimental study, treatment with AT was shown to improve survival in AP (Bleeker et al 
1992), to prevent cerulein-induced AP, and to inhibit secretion of cytokines and HMGB1 
(Hagiwara et al 2009). However, infusion of AT in patients with sepsis has not been shown to 
reduce mortality in a clinical setting (Afshari et al 2007; Levi et al 2008). Opposite results 
have also been reported in experimental and small clinical studies (Roemisch et al 2002; 
Wiedermann 2006).   
 
2.6.3.12 Fibrin and plasminogen-plasmin system  
The production of fibrinogen is increased in inflammation, and fibrinogen and fibrin increase 
the production of proinflammatory cytokines and chemokines (Esmon 2005b). Fibrinolysis is 
essential for removing the formed clot, and it is mediated by plasmin. Plasmin cleaves fibrin, 
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resulting in the production of fibrin degradation products (D-dimer) (Adams and Bird 2009).
Plasmin is produced as a result of proteolytic cleavage of plasminogen by tissue-type 
plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA). T-PA and u-
PA are regulated by PAI. In inflammation, also PAI levels are increased, and fibrinolytic 
activity is decreased. (Esmon 2004b) 
 
Figure 8. Acute pancreatitis is characterized by activation of inflammation, coagulation and the 
complement system. 
 
2.7 Treatment of acute pancreatitis 
There is no specific treatment for AP. Several pharmacologic therapies have been proposed, 
but none have proven to have clinical benefit in randomized controlled trials. Currently, the 
therapy for AP is mainly supportive. This includes adequate fluid resuscitation, monitoring for 
47 
 
hypoxemia and relief of pain. Nearly half of the patients with severe AP have OF and require 
management in the intensive care unit (Neoptolemos et al 1998; Swaroop et al 2004). 
The aim of intravenous fluid resuscitation in AP is to adequately perfuse the pancreatic 
microcirculation, and to minimize and prevent pancreatic necrosis and its complications 
(Tenner 2004). Although there is widespread acceptance of the importance of aggressive 
fluid resuscitation in AP, only few clinical studies have been carried out in, and there are no 
published studies on humans, in which targeted outcome measures have been used 
(Gardner et al 2008). In animal studies, the benefits of fluid resuscitation (improvements in 
circulations and survival) (Niederau et al 1988; Juvonen et al 1999) have been 
demonstrated, and there is some evidence that colloid solutions might be more effective than 
crystalloids (Gardner et al 2008).  
Infection of pancreatic necrosis is the major cause of morbidity and mortality in AP after the 
first 1-2 weeks of disease onset. Prophylactic antibiotic treatment has therefore been used. 
Several studies have nevertheless presented controversial results on the benefits of this 
treatment. A recent review of 7 meta-analyses, 7 reviews and some clinical studies 
concluded that antibiotic prophylaxis should not be used in patients with necrotizing 
pancreatitis. Instead, a more measured, on-demand use of antibiotics was recommended, 
and antibiotics should be added if signs and symptoms of infection are present (e.g. fever, 
leukocytosis, positive results of cultures, hemodynamic instability or OF). (Segarra-Newnham 
and Hough 2009)  
Currently, enteral feeding (with a nasogastric or nasojejunal tube) is considered to be the 
preferred method of delivering nutrition in severe AP, instead of total parenteral nutrition 
(TPN). Two meta-analyses of randomized trials found that patients with enteral nutrition had 
an overall reduction in infections and in the need for pancreatic surgery, and a lower mortality 
rate than did patients with TPN (Marik and Zaloga 2004; Petrov et al 2008). 
Patients with mild AP and sterile pancreatic necrosis should be treated conservatively. The 
development of infected pancreatic necrosis is an indication for intervention, usually surgical. 
However, early surgery (within the first 2 weeks) should be avoided, if possible because it is 
associated with increased mortality (Whitcomb 2006; Tonsi et al 2009). (Banks et al 2006; 
Forsmark et al 2007) If abdominal compartment syndrome is recognized, prompt treatment 
by decompressive laparotomy might be needed (Leppaniemi et al 2007). ERCP is 
recommended in the management of acute biliary pancreatitis, if clinical or radiographic 
findings suggest obstruction, e.g. due to a persistent common bile duct stone, or when acute 
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cholangitis is present. Cholecystectomy is also recommended in 2-4 weeks after discharge to 
prevent relapses. If the patient is not fit for surgery, an endoscopic sphincterotomy is a 
reasonable alternative (Alexakis and Neoptolemos 2005). (Beger and Rau 2007; Forsmark et 
al 2007; Pandol et al 2007) 
 
2.8 Prognosis of acute pancreatitis 
10% of severe AP patients who survive the initial episode die within a few years due to 
alcoholism and pancreas-related disease, mainly diabetes. The long-term health-related 
quality of life (HRQL) of the survivors is similar to that of the normal population. (Halonen et 
al 2003) However, in the first year after necrotizing AP, the patients show improvement in 
their physiological components of quality of life and their physical function, but their outcome 
at one year is still poor compared to the general population (Wright et al 2009). About one 
half of the patients with a first attack of alcohol-related AP will develop a recurrent attack. A 
mild first attack is also a risk factor for multiple recurrences. Continuous alcohol consumption 
is a risk factor for overall recurrence. (Pelli et al 2008) After follow-up, 30% of patients with 
alcohol-induced severe AP had remained abstinent, and 28% were problem drinkers, 
alcohol-dependent or alcoholics; 87% of all severe AP patients had returned to work 
(Halonen et al 2003). After the first episode of alcohol AP, about one third of the patients 
developed impaired glucose metabolism, but exocrine dysfunction did not persist during the 
follow-up (Pelli et al 2009). The proportion of patients with chronic changes detected by 
secretin-stimulated magnetic resonance pancreatography (SMRP) increased from one fifth to 
one half, regardless of continuing alcohol consumption during the follow-up, and chronic 
pseudocysts detected by SMRP were found to be a risk factor for recurrent pancreatitis (Pelli 
et al 2009).  
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3 PRESENT INVESTIGATION 
 
3.1 Aims of the study 
The aim of the present study was to investigate inflammatory and coagulation disturbances 
in AP. The specific aims were: 
1. To study how the PC pathway evolves during the course of severe AP, and to assess 
the plasma thrombin formation capacity in patients with AP; to determine whether a 
failure of the PC pathway homeostasis is associated with the development of OF, and 
to find out whether the levels and functions of individual coagulation factors are 
associated with the severity and fatal outcome in AP patients. 
2. To study the serum levels of CD59, and the plasma levels of sRAGE and HMGB1 in 
patients with AP; to examine how these levels are related to the development of OF 
and mortality in patients with AP.  
3. To find inflammatory or coagulation markers for predicting the development of OF or 
fatal outcome in AP.   
 
3.2 Materials and Methods 
3.2.1 Patients 
The Ethics Committee of the Helsinki University Central Hospital approved the study 
protocols, and the informed consent of each patient was obtained. All of the patients studied 
had AP and were admitted to Helsinki University Central Hospital within 72 h of the onset of 
symptoms. During the entire study period (between August 1998 - June 2004) the Pancreas 
Study Group of the University of Helsinki collected prospectively AP patients, and the patient 
series (I-IV) were chosen from these patients. Every patient series (I-IV) was comprised of 
different patients.   
I) The study population consisted of 31 patients with severe AP treated in the intensive care 
unit between April 2001 and February 2003. OF developed in 13 patients (Grade 2); the 
remaining 18 patients without OF (Grade 1) served as controls (Table 3). 
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Table 3. Characteristics of the patients (Study I) 
 Grade 1 (n=18) Grade 2 (n=13) 
Age * 44 (24-75) 47 (31-83) 
Gender (female/male)# 7/11 1/12 
Etiology   
   Alcohol # 15 11 
   Gallstone # 3 2 
Mortality # 0 3 
* Years, median (range) 
# Number of patients  
 
II) The study comprised 12 AP patients with OF and 27 control AP patients admitted to the 
hospital between August 1998 and July 2000. For each of the 12 OF patients (Grade 2) two 
to three age-matched (+/- 10 years) control patients were included. Of these patients, 13 had 
mild AP (Grade 0) and 14 severe AP without OF (Grade 1) (Table 4). 
Table 4. Characteristics of the patients (Study II) 
 Grade 0 (n=13) Grade 1 (n=14) Grade 2 (n=12) 
Age * 43 (28-77) 52 (32-81) 50 (27-74) 
Gender 
(female/male)# 
5/8 2/12 2/10 
Etiology    
   Alcohol # 10 10 10 
   Gallstone # 1 3 2 
   Unknown # 2 1 0 
Mortality # 0 0 4 
* Years, median (range) 
# Number of patients 
  
III) The study included 455 AP patients admitted to the hospital between September 1998 
and May 2004. 38 patients had OF (Grade 2), and a control group of 127 patients was 
randomly selected from the 417 patients without OF. In the control group, 89 patients had 
mild AP (Grade 0) and 38 severe AP without OF (Grade 1) (Table 5). 
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Table 5. Characteristics of the patients (Study III) 
 Grade 0 (n=89) Grade 1 (n=38) Grade 2 (n=38) 
Age * 47 (19-87) 51 (20-79) 48 (27-88) 
Gender 
(female/male)# 
38/51 10/28 7/31 
Etiology    
   Alcohol # 55 29 31 
   Gallstone # 21 5 5 
   Unknown # 13 4 2 
Mortality # 0 0 11 
* Years, median (range) 
# Number of patients 
 
IV) The study comprised 9 AP patients with OF (Grade 2) and 24 control AP patients 
admitted to the hospital between September 2001 and June 2004. For each of the 9 OF 
patients, one to two age-matched (+/- 10 years) control patients were included. Of these 
patients, 11 had mild AP (Grade 0) and 13 severe AP without OF (Grade 1) (Table 6). Also 
the thrombograms of 9 healthy individuals were analyzed. 
Table 6. Characteristics of the patients (Study IV) 
 Grade 0 (n=11) Grade 1 (n=13) Grade 2 (n=9) 
Age * 46 (26-83) 46 (36-92) 46 (27-83) 
Gender 
(female/male)# 
4/7 3/10 2/7 
Etiology    
   Alcohol # 7 10 7 
   Gallstone # 2 3 1 
   Unknown # 2 0 1 
Mortality # 0 0 4 
* Years, median (range) 
# Number of patients 
 
3.2.2 Diagnosis and Classification 
The diagnosis of AP was based on typical clinical findings, including onset of epigastric pain, 
nausea and vomiting, and an elevated serum or plasma amylase concentration of at least 2- 
or 3-fold the upper reference limit, and/or typical radiological appearance of AP on CT scan. 
The included patients were retrospectively categorized into those with mild AP or severe AP 
according to the Atlanta classification (Bradley 1993). The patients with severe AP were 
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further subcategorized into those with local complications only (including necrosis, an 
abscess or a pseudocyst), and recovering without OF, and into those with OF. OF was 
defined as a development of respiratory failure necessitating mechanical ventilation, and/or 
renal failure necessitating hemodialysis. The criteria for initiating mechanical ventilation were 
tachypnea (respiratory rate >35/min) and/or the need for an inspiratory oxygen fraction >0.6 
in order to maintain arterial partial pressure of oxygen >8 kPa. Hemodialysis was started in 
patients with significantly impaired renal function as indicated by increased concentrations of 
serum creatinine (>300 umol/l) and serum urea (>40 mmol/l) and progressive metabolic 
acidosis (pH <7.28) in serial measurements, regardless of urine output.  
 
3.2.3 Scoring systems 
Two scoring systems were used to describe the patients’ clinical condition. Appropriate 
physiological and laboratory data were collected from patient records to calculate APACHE II 
score (II-IV) and SOFA score (II). 
 
3.2.4 Analytical Methods 
3.2.4.1 Blood samples 
I) Blood samples for determining PC, APC and flow cytometry were taken every second day 
during the patient’s stay in the intensive care unit (Table 7). The samples were 
anticoagulated. Immediately after withdrawal, the blood samples for flow cytometry were 
cooled in an ice-cold water bath, and kept at 0oC until processed within 24 h. From the rest of 
the sample, plasma was separated by centrifugation at +4oC and stored in aliquots at -70oC. 
Samples on admission (defined as sampling within 36 h of actual admission) were available 
from 11 Grade 2 patients and 15 Grade 1 patients. OF developed in -2-14 days (median, 1 
day) after admission to the research hospital. Samples preceding the diagnosis of OF were 
available from only five patients. Follow-up samples with a maximum 2-day interval for 10 
days were available from nine Grade 2 patients. 
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Table 7. Collection of blood samples (Study I) 
Time (day) Every second day *, starting from day 1 
* Every second day during the patient’s stay in the intensive care unit; length of the stay in 
the intensive care unit, median (range): in Grade 2 patients 26 days (2-129) and in Grade 1 
patients 6 days (2-20) 
II) Serum samples for determining CD59 were collected on admission, and on days 1 and 3-
7 post admission (Table 8). After coagulation and centrifugation, the samples were frozen 
and stored at -70oC. 
Table 8. Collection of serum samples (Study II) 
Time (day) On admission 1 3-7 * 
* The first available sample for the time period was used 
III) Plasma samples for determining sRAGE and HMGB1 were collected on admission, and 
on days 1 and 2, days 3 and 4, and days 7 and 12 after admission (Table 9). After 
anticoagulation and centrifugation, the samples were frozen and stored at -70oC. 
For determining sRAGE, samples were available on admission from 79 Grade 0, 38 Grade 1 
and 34 Grade 2 patients. On days 1 and 2, these samples were available from 78 Grade 0, 
28 Grade 1 and 29 Grade 2 patients. On days 3 and 4, samples were available from 55 
Grade 0, 24 Grade 1 and 23 Grade 2 patients. On days 7 and 12, samples were available 
from 10 Grade 0, 17 Grade 1 and 25 Grade 2 patients. 
For determining HMGB1, samples were available on admission from 67 Grade 0, 35 Grade 1 
and 29 Grade 2 patients. On days 1 and 2, these samples were available from 73 Grade 0, 
24 Grade 1 and 26 Grade 2 patients. On days 3 and 4, samples were available from 45 
Grade 0, 19 Grade 1 and 25 Grade 2 patients. On days 7 and 12, samples were available 
from 9 Grade 0, 17 Grade 1 and 23 Grade 2 patients. 
Table 9. Collection of plasma samples (Study III) 
Time (day) On admission 1-2 * 3-4 * 7-12 * 
* The first available sample for each time period was used 
IV) Plasma samples for determining F1+2, TFPI (free and total) and thrombogram were 
collected on admission (Table 10). After anticoagulation and centrifugation, the samples 
were frozen and stored at -70oC. 
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Table 10. Collection of plasma samples (Study IV) 
Time (day) On admission 
 
 
3.2.4.2 Laboratory tests 
The plasma levels of PC and APC were determined by enzyme capture assay in the 
laboratory of Professor J.H. Griffin, Department of Molecular and Experimental Medicine, 
The Scripps Research Institute, La Jolla, CA, USA (I). Briefly, a monoclonal antibody against 
PC and APC was immobilized in microplates. Plasma samples supplemented with 
benzamidine, a reversible inhibitor of thrombin, APC, and trypsin-like proteases, were 
incubated in the wells for the capture of APC and PC. The plates were then washed to 
remove sample constituents and benzamidine. The amidolytic activity of the captured APC 
was measured with chromogenic substrate S-2366 (Chromogenix AB, Mölndal, Sweden). 
Assays were run in duplicate, and a noncommercial plasma pool containing benzamidine 
was used as a standard. The total PC was measured by activating the bound PC in the wells 
by Protac (American Diagnostica, Greenwich, CT, USA). The amidolytic activity was then 
measured with the chromogenic substrate S-2366 (Chromogenix AB). The amidolytic activity 
observed after Protac activation is essentially equal to the total PC. Assays were run in 
duplicate.  
CD59 levels were measured by means of a sandwich enzyme immunoassay in the 
laboratory of Professor S. Meri, Haartman Institute, University of Helsinki, Finland (II). Rat 
mAb YTH53.1 against human CD59 was originally provided by Professor H. Waldmann (Sir 
William Dunn School of Pathology, Oxford, UK). Nunc Maxisorp microtiter plates were coated 
with YTH53.1 (5 ug/ml in 0.1 M NaHCO3, pH 8.5) overnight at +4
oC. The wells were washed 
with phosphate-buffered saline (PBS)/0.02% Tween 20, and the samples, diluted 1:20 in 
washing buffer, were added. CD59 was purified from urine as described previously (Lehto et 
al 1995) and used as standard at concentrations of 0-40 ng/ml. The samples were incubated 
for 1 h at room temperature, the wells were washed and the primary antibody goat-anti-
human CD59 (a gift from Professor F. Tedesco, Department of Physiology and Pathology, 
University of Trieste, Trieste, Italy) diluted 1:2000 in PBS/Tween was added. After 1 h of 
incubation, the plates were washed and horseradish peroxidase (HRP)-conjugated rabbit-
anti-goat antibody (Dakopatts, Denmark) diluted 1:5000 in PBS/Tween with 1% rat serum 
was added. The plates were incubated for 1 h at RT, washed with PBS/Tween and the OPD 
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substrate (Dakopatts) was added. The reaction was stopped with 2 M H2SO4 and colour 
formation was measured with a spectrophotometer. 
The levels of sRAGE in the plasma samples were measured by DuoSet human RAGE 
enzyme-linked immunosorbent assay (ELISA; R&D Systems, Minneapolis, Minn, USA) in the 
laboratory of Professor H. Rauvala, Neuroscience Center, University of Helsinki, Finland (III).  
Plasma HMGB1 levels were measured by combined heparin-Sepharose precipitation and 
Western blotting in the laboratory of Professor H. Rauvala, Neuroscience Center, University 
of Helsinki, Finland (III). Briefly, the plasma samples were centrifuged at 14,000-15,000g for 
2 min, and 120 uL of supernatant were collected. 60 uL of 50% heparin-Sepharose slurry in 
phosphate-buffered saline containing 1.2 mol/L NaCl were added to the supernatants. The 
samples were mixed by rotation at 4oC for 1-2 h, after which the supernatant was removed 
and the gel washed with phosphate-buffered saline. Heparin-Sepharose-bound proteins were 
eluted with 30 uL of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
sample buffer by incubating at 99oC for 5 min in a shaker. 15 uL of the samples were 
electrophoresed in SDS-PAGE and analyzed in Western blot gels probed with chicken anti-
HMGB1 immunoglobulin Y32 and peroxidase conjugated anti-chicken antibodies (Zymed 
Laboratories, San Francisco, CA, USA). Normal plasma samples containing known amounts 
of recombinant HMGB1 were analyzed equally in each gel, and a standard curve was 
generated. Recombinant HMGB1 protein was produced as described (Parkkinen et al 1993), 
and the protein concentration was determined by measuring absorbance at 280 nm, whereas 
protein purity was determined by SDS-PAGE analysis. A standard curve was accomplished 
by adding a known amount of recombinant HMGB1 to normal human plasma, which is 
virtually free of HMGB1 (Rouhiainen et al 2000). Optical densities of the immunoreactive 30-
kD bands were quantified as described (Rouhiainen et al 2004; Sunden-Cullberg et al 2006). 
The F1+2 levels in the plasma samples were measured by Enzygnost* F1+2 micro ELISA 
(Dade Behring Inc., Marburg, Germany) (IV). The TFPI (free and total) levels in the plasma 
samples were measured by AsserachromR free and total TFPI ELISA (Diagnostica Stago, 
Asnieres-Sur-Seine, France) (IV). These measurements were performed in the Haematology 
Laboratory, Helsinki University Central Hospital, Finland. 
Values for routine coagulation parameters (PT, D-dimer, and platelet count) (I), (PT, APTT, 
and platelet count) (IV) and CRP (III, IV) were determined in accordance with the hospital 
routine laboratory practice. 
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3.2.4.3 Flow cytometry (I) 
APC acts in vitro as an anti-inflammatory agent mainly by modulating monocyte activation 
during inflammation (Grey et al 1994; White et al 2000; Yuksel et al 2002). Monocyte HLA-
DR expression reflects the recent history of activation/functional suppression of the 
circulating monocyte population (Kylanpaa-Back et al 2001). HLA-DR was determined with 
cytometry of whole blood flow, as described previously (Kylanpaa-Back et al 2001; Mentula 
et al 2003). The determinations were done at the Department of Bacteriology and 
Immunology, Haartman Institute, University of Helsinki, Finland. The mAbs were 
phycoerythrin-conjugated anti-HLA-DR mAb (IgG2a, clone L243), phycoerythrin-conjugated 
irrelevant mAb (IgG2a, clone X39), and fluorescein isothiocyanate-conjugated anti-CD14 
mAb (IgG2b, clone MFP9) (Becton Dickinson, San Jose, CA, USA). HLA-DR expression is 
defined as the proportion of positively fluorescing monocytes (HLA-DR%). 
 
3.2.4.4 Thrombogram (IV) 
The thrombograms were obtained through Calibrated Automated Thrombography (CAT) in 
the Haematology Laboratory of Helsinki University Central Hospital, Finland. The parameters 
of the thrombogram are: lag time, area under the curve (AUC=endogenous thrombin 
potential ETP), peak height, and time to reach the peak (Hemker et al 2002). Platelet-poor 
plasma (PPP) was used. Coagulation was triggered by recalcification in the presence of 5 
pM TF. Experiments were carried out in the absence or in the presence of APC at various 
concentrations (1 nM and 2.5 nM). 
 
3.2.5 Statistical Methods 
The results were expressed as medians and ranges or inter-quartile ranges (IQR). 
Comparisons between two groups were done by the Mann-Whitney U test (I-IV). For 
comparing three groups, the Kruskall-Wallis test (III, IV) and the Jonkheere-Terpstra test for 
trend (IV) were used. The P values were corrected by the Bonferroni method (III). When the 
Kruskall-Wallis test result was significant, the Dunn post hoc test (III, IV) was used to test 
significance of differences between the 3 groups. Fisher’s exact test (I) or Chi-square tests (I, 
III) were used for comparison of proportions. Comparison of the follow-up samples was done 
with Wilcoxon signed rank test (III) or Friedman’s test (I, III), followed by Dunn’s test for post 
hoc comparisons (I). Spearman’s rank correlation was used for assessing correlations (I-IV). 
Optimal cutoff levels for values and markers were determined using receiver-operator 
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characteristic (ROC) curves (I, II, IV). Sensitivity, specificity and positive and negative 
likelihood ratios (LRs) were calculated with 95% confidence intervals (CI) according to the 
efficient-score method, and corrected for continuity (II). Statistical analyses were performed 
using the SPSS statistical software (Chicago, IL, USA). P<0.05 was considered statistically 
significant. 
 
3.3 Results 
3.3.1 Upregulated but insufficient generation of activated protein C in 
severe acute pancreatitis (I) 
In this study there were 13 patients with severe AP and OF (Grade 2), and 18 patients with 
severe AP without OF (Grade 1). Grade 2 patients were compared with Grade 1 patients. 
Three patients died (10% of all patients) and they were Grade 2 patients (23% of Grade 2 
patients).  
During the observation period, decreased PC values (<70% of the adult mean) were a 
frequent finding, occurring in 43% of all samples (68% of all patients) at various stages of the 
disease. All but one of the APC values fell within the range observed in healthy resting 
adults. The APC/PC ratio did not fall below the lower limit of normal in any sample, but 
exceeded the upper normal limit in 40% of the samples. At least one APC/PC ratio value was 
above normal in 74% of all patients. The intrapatient PC levels varied greatly from day to 
day. The levels of APC showed much less variation than did the PC levels. 
On admission to hospital, the APC concentration was significantly lower in Grade 2 patients 
than in Grade 1 patients (median APC 86% vs 105%, p=0.027), whereas the PC level and 
the APC/PC ratio did not differ significantly between the two groups. However, 89% of Grade 
2 patients and 43% of Grade 1 patients showed an abnormally high APC/PC ratio. 
During the first two weeks of hospitalization, low PC levels occurred in 92% of Grade 2 
patients and 44% of Grade 1 patients (p=0.008). The minimum APC level was lower in Grade 
2 patients than in Grade 1 patients (median 85% vs 97%, p=0.009) (Table 11). Using 87% as 
the cutoff value, 8/13 (62%) of Grade 2 patients and 3/18 (17%) of Grade 1 patients had 
reduced APC levels (p=0.021). A total of 92% Grade 2 patients and 50% of Grade 1 patients 
had APC/PC ratios exceeding the upper normal limit (p=0.02).  
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Table 11. Activated protein C and protein C levels, their ratios, and the proportion of positively 
fluorescing monocytes (HLA-DR%) in patients with organ failure (Grade 2) and without organ failure 
(Grade 1) during their stay in the intensive care unit. 
Variable Grade 2 Grade 1 p-value 
Lowest APC level 
(%) 
85 (76-102) 97 (73-136) 0.009 
Lowest PC level (%) 52 (8-70) 70 (18-113) 0.03 
Lowest APC/PC ratio 1.1 (0.87-13.2) 1.3 (1.0-3.8) 0.02 
Highest APC/PC ratio 1.8 (1.5-13.2) 1.6 (1.2-4.1) 0.03 
HLA-DR% 46 (8-82) 44 (11-84) 0.80 
Data presented as median (range) 
APC=activated protein C, PC=protein C 
 
There was no difference in HLA-DR% between Grade 2 and Grade 1 patients during their 
stay in the intensive care unit (Table 11). HLA-DR-positive monocytes correlated with PC 
levels (R=0.38, p<0.001) and APC levels (R=0.27, p<0.001), indicating that the PC pathway 
was associated with systemic inflammation-triggered immune suppression. 
The plasma samples of Grade 2 patients drawn before OF, and compared with those of 
Grade 1 patients, showed equal APC levels (p=0.56), low PC levels (p=0.025) and high 
APC/PC ratios (p=0.02). In the subgroup of patients with OF (n=9) during a 10-day follow-up, 
both the APC and the PC levels tended to increase (Figure 9). The median APC/PC ratio 
was the lowest on day 7. The apparent mechanism for the decreasing APC/PC ratio during 
hospitalization was a gradual improvement of PC levels, without a concomitant increase in 
APC values. There was thus a trend of gradual improvement of early PC pathway 
disturbances during the course of OF.  
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Figure 9. Follow-up concentrations of a) protein C (PC), b) activated protein C (APC), and c) APC/PC 
ratio during the stay in hospital in nine patients with organ failure. The time of sampling did not 
influence any parameter statistically significantly (Friedman’s test >0.05). 
 
In the three non-survivors, the median level of APC was 105% (85-188), that of PC was 74% 
(8-165), and that of the APC/PC ratio was 1.45 (1.13-13.2). In the 10 surviving Grade 2 
patients, the median level of APC was 98% (76-109), that of PC was 71% (35-165), and that 
of the APC/PC ratio was 1.32 (0.87-2.6).  
 
3.3.2 Disturbed tissue factor regulation in acute pancreatitis (IV) 
In this study there were 9 patients with severe AP and OF (Grade 2), 13 patients with severe 
AP but without OF (Grade 1), and 11 patients with mild AP (Grade 0). The Grade 2 patients 
were compared with Grade 0 and Grade 1 patients. Four patients died (12% of all patients); 
they were all Grade 2 patients (44% of Grade 2 patients). For the thrombogram analyses, the 
thrombograms of 9 healthy individuals served as controls. 
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On admission, there was no significant difference in F1+2 levels between the patient groups.  
The thrombograms of all patients, as compared with healthy reference subjects, were 
variable and disturbed in their shape (Figure 10). In 11 patients [7 (78%) Grade 2 patients, 4 
(31%) Grade 1 patients and 0 (0%) Grade 0 patients, p=0.001] the standard TF stimulation 
did not trigger thrombin generation at all, and their thrombogram lines were thus ‘flat’. There 
was a significant increase in lag time and time to peak values associated with severity of AP, 
but the differences in other thrombogram variables between the patient groups were not 
statistically significant. When the experiments were carried out in the presence of APC (1 
and 2.5 nM), there were no significant differences in thrombogram variables between the 
patient groups.  
 
 
 Figure 10. The thrombograms of patient groups and healthy controls. The black line represents a 
mean curve.  
 
The differences between the patient groups were statistically significant at levels of free TFPI 
and in ratios of free and total TFPI. There was a significant rising trend in free and total TFPI 
levels, and in the ratios of free and total TFPI, which was associated with the severity of AP 
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(Figure 11). The differences between patients showing thrombin generation (n=22) and 
patients with ‘flat’ thrombograms (n=11) were significant in free TFPI levels and TFPI ratios, 
but not in total TFPI levels. The correlation between F1+2 levels and free (R=0.053, p=0.771) 
and total (R=0.247, p=0.166) TFPI levels and their ratios (R=-0.044, p=0.809) was not 
significant. In patients (n=22) whose thrombin generation started in the CAT, the correlation 
between total TFPI levels and lagtime values was significant (R=0.442, p=0.04), but not 
between free TFPI levels (R=0.376, p=0.085) or TFPI ratios (R=0.244, p=0.274) and lag time 
values. 
 
          
Figure 11. Dot blots showing the plasma (left) free and (middle) total tissue factor pathway inhibitor 
(TFPI) levels and (right) their ratios on admission. Grade 0, mild AP; Grade 1, severe acute 
pancreatitis, but no organ failure; and Grade 2, severe acute pancreatitis and organ failure. Error bars 
show the mean and 95% confidence interval of the mean for each group. Statistical significances 
between the groups after the Kruskall-Wallis and Dunn’s post hoc test are shown above, and P values 
for the trend between the groups by Jonkheere-Terpstra test are shown at the bottom. 
 
On admission, the difference in F1+2 levels between survivors (n=29) and non-survivors 
(n=4) was not significant. All non-survivors presented with a ‘flat curve’ in the CAT. The 
difference between survivors and non-survivors in free TFPI levels and TFPI ratios was 
significant, but not in total TFPI levels. Since free TFPI is evidently associated with the 
progressive severity of AP and the ‘flat curve’ in CAT, and consequently, the ‘flat curve’ in 
CAT is associated with fatal outcome, the predictive capability of these measurements was 
analyzed in relation to mortality. When the ‘flat curve’ was used on admission alone, the 
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sensitivity/specificity of predicting fatal outcome was 100/36%, respectively. Combining this 
with free TFPI (cutoff 25 ng/ml) increased the specificity to 50%. 
 
3.3.3 Elevated levels of CD59 in severe acute pancreatitis (II) 
In this study there were 12 patients with severe AP and OF (Grade 2), 14 patients with 
severe AP and without OF (Grade 1), and 13 patients with mild AP (Grade 0). Grade 2 
patients were compared with Grade 0 and Grade 1 patients. Four patients died (10% of all 
patients); they were all Grade 2 patients (33% of Grade 2 patients).  
On admission, the serum CD59 levels of all patients correlated significantly (p<0.05) with 
their CRP levels (R=0.40) and APACHE II scores (R=0.32). On day 1, the CD59 levels 
correlated significantly with the CRP levels (R=0.37, p<0.05) and APACHE II scores (R=0.52, 
p=0.01). A significant correlation with CRP and CD59 was seen also on days 3-7 (R=0.38, 
p<0.05). 
On admission, the median serum CD59 levels were significantly higher (p=0.002) in Grade 2 
(median 104.2 ng/ml, range 26.1-186.3) than in Grade 0 patients (37.3 ng/ml, range 30.3-
75.9) and in Grade 1 patients (38.6 ng/ml, range 19.9-96.1). The CD59 levels remained 
higher in Grade 2 patients than in Grade 0 and Grade 1 patients on day 1 (p=0.001) and 
days 3-7 (p=0.002). The overall serum CD59 levels were higher in Grade 2 patients than in 
Grade 0 and Grade 1 patients (p<0.001). The serum CD59 levels remained stable during the 
observation period in Grade 0 and Grade 1 patients, and also in Grade 2 patients, except in 
two patients whose levels increased toward the end of the observation period. 
The sensitivity, specificity, positive and negative likelihood ratios (LR) for CD59, CRP and 
APACHE II scores and their 95% confidence intervals (CI) in predicting OF are given in 
Table 12. 
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Table 12. Sensitivity, specificity, positive and negative likelihood ratio (LR) and their 95% confidence 
intervals (CI) in predicting organ failure in acute pancreatitis. 
Time Marker and 
cutoff * 
Sensitivity 
(%) (95% CI) 
# 
Specificity 
(%) (95% CI) 
# 
Positive LR 
(95% CI) # 
Negative LR 
(95% CI) # 
Day 0 CD59>89 67 (35-89) 96 (79-100) 18 (2.5-128) 0.35 (0.16-
0.77) 
 CRP>188 67 (35-89) 81 (61-93) 3.6 (1.5-8.7) 0.41 (0.18-
0.93) 
 APACHE II 
>7 
67 (35-89) 74 (53-88) 2.6 (1.2-5.5) 0.45 (0.20-
1.03) 
Abbreviations: CRP=C-reactive protein; APACHE=acute physiology and chronic health 
evaluation 
* Determined using receiver-operator characteristic (ROC) curves 
# Calculated according to the efficient-score method and corrected for continuity 
 
 
3.3.4 sRAGE and HMGB1 in patients with acute pancreatitis (III) 
In this study there were 38 patients with severe AP and OF (Grade 2), 38 patients with 
severe AP but without OF (Grade 1), and 89 patients with mild AP (Grade 0). Grade 2 
patients were compared with Grade 0 and Grade 1 patients. In addition, the Grade 0 and 
Grade 1 patients were combined into a single control group (Grades 0 + 1), and this group 
was compared with Grade 2 patients. 11 patients died (7% of all patients); they were all 
Grade 2 patients (29% of Grade 2 patients).  
On admission and on days 1 and 2, the difference in plasma sRAGE levels was significant 
only between Grade 0 and Grade 1 patients. On days 3 and 4, the sRAGE level was 
significantly higher in Grade 2 than in Grade 0 (p<0.05) and Grade 1 patients (p<0.001). The 
highest measured sRAGE levels were also higher in Grade 2 than in Grade 1 patients 
(p<0.01). On days 7 and 12, there was no statistically significant difference between the 3 
groups (Figure 12). 
The median of the highest measured sRAGE levels was higher in Grade 2 patients (472 
pg/ml; IQR, 259-912) than in Grades 0 + 1 patients (349 pg/ml; IQR, 209-544; p=0.024). 
Analysis of the time course of the increase in sRAGE levels in Grade 2 patients revealed a 
rising trend up until days 3 and 4 (p=0.019). Thereafter, the median sRAGE level fell, and 
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was lower on days 7 and 12 (253 pg/ml; IQR, 141-567; n=16) than on days 3 and 4 (536 
pg/ml; IQR, 377-1112; p=0.003). In 72 of the 89 Grades 0 + 1 patients, from whom plasma 
samples were available at each of the 3 time points, the median sRAGE levels on day 0, 
days 1 and 2, and days 3 and 4 were rather similar (p=0.14). 
 
Figure 12. Box plots showing the plasma sRAGE levels (median, interquartile range, highest and 
lowest values, outliers) during the course of AP. Grade 0, mild AP; Grade 1, severe AP, but no organ 
failure; and Grade 2, severe AP and organ failure. P values for the significance of differences between 
the groups by Kruskall-Wallis test are shown. P values at different time points were corrected by the 
Bonferroni method. Post hoc test was done using Dunn’s test, and the level of significance between 
the 2 groups is shown with asterisks (*P<0.05; **P<0.01; ***P<0.001; and n.s., not significant).  
 
The proportion of patients with detectable HMGB1 (>30 ng/ml) did not differ significantly 
between the 3 groups of AP severity at any time point (p>0.05) (Figure 13). Among the 
patients with detectable HMGB1, the median values of the highest levels between the groups 
(Grade 2 patients vs Grades 0 + 1 patients) were similar (p=0.31). 
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Figure 13. Dot plots showing the plasma HMGB1 levels during the course of AP. Grade 0, mild AP; 
Grade 1, severe AP, but no organ failure; and Grade 2, severe AP and organ failure. The dots below 
the broken line represent measurements of the patients with a HMGB1 level below the detection limit 
(30 ng/ml). The proportion of patients with detectable HMGB1 at each time point is shown below the 
graph; the differences between the 3 groups were not significant.  
 
The median of the highest sRAGE levels of non-survivors (561 pg/ml; IQR, 379-1184, n=11) 
was higher than that of the survivors (360 pg/ml; IQR, 219-558; n=154; p=0.010). The 
median of the highest sRAGE levels of the non-surviving Grade 2 patients was higher than 
that of the Grade 2 survivors, but the difference was not significant (p=0.085). The HMGB1 of 
Grade 2 patients was detectable in 18 (67%) of the 27 survivors and in 6 (60%) of the 11 
(55%) non-survivors (p=0.48). 
 
3.3.5 Markers predicting organ failure and fatal outcome (I-IV) 
AP patients with OF showed low PC levels, reduced APC levels and high APC/PC ratios 
compared with patients without OF. Plasma samples drawn immediately prior to OF showed 
also low PC levels and high APC/PC ratios. (I) 
AP patients with OF had higher free TFPI levels, and free and total TFPI ratios compared 
with patients without OF. These levels were higher also in non-survivors than in survivors. All 
non-survivors had a ‘flat curve’ in the thrombogram. (IV) 
AP patients with OF had higher CD59 levels than did patients without OF, and these levels 
remained higher during the first week of hospitalization. (II) 
AP patients with OF had higher sRAGE levels than did patients without OF. The median of 
the highest sRAGE levels of non-survivors was higher than that of the survivors. (III)  
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3.4 Discussion 
3.4.1 Coagulation disturbances in acute pancreatitis (I, IV) 
In the first study we found that the minimum levels of APC were significantly lower in OF 
patients than in severe AP patients without OF. The PC deficiency was therefore logically 
associated with a decrease of APC levels in patients with OF. A more significant finding, 
however, may be that the APC levels did not seem to be grossly elevated. In fact, only one 
sample from one patient showed an absolute APC level that exceeded the reported upper 
limit of normality (200%) (Petaja et al 1998). Thrombin is the APC activator, and APC is a 
feedback inhibitor for thrombin generation (Griffin 1995; Esmon 2001). The complicated 
balance between thrombin, PC and APC varies depending on the circumstances. In resting 
healthy adults, the PC level, rather than thrombin level, may be the major determinant of the 
circulating APC level (Fernandez et al 1997; Petaja et al 1998; Petaja et al 1999). On the 
other hand, it has been reported that the most pronounced and rapid enhancements from 
normal resting APC levels to levels typically ranging from 250% to over 800% of the normal 
mean have occurred during the first minutes of reperfusion in liver transplantation and during 
a proinflammatory infusion in renal transplantation (Ilmakunnas et al 2003; Turunen et al 
2005). In a sepsis study, it was found that despite ongoing activation of coagulation, 25% of 
patients failed to increase their APC levels above 250% (while 75% had levels ranging from 
approximately 250-800%) (Liaw et al 2004). It was concluded that the septic patients varied 
considerably in their ability to generate APC in response to the physiological thrombin 
stimulus, and the phenomenon was attributed to endothelial dysfunction (Liaw et al 2004). 
This is in accordance with our findings, suggesting that the lack of elevated free APC levels 
in the presence of activated coagulation in patients with AP in most cases reflected 
dysfunctional PC activation on the endothelium, or possibly enhanced inhibition of APC by 
plasma protease inhibitors. It is possible, however, that significant PC deficiency could also 
be rate-limiting for APC formation in patients with severe AP. 
In the fourth study our results showed that the thrombograms of AP patients were variable 
and disturbed in their shape. The thrombin generation of AP patients varied greatly, and 
there were even 11 patients whose thrombin generation was not triggered at all by standard 
TF stimulation. In patients whose thrombin generation started, the severity of AP correlated 
significantly with the lag time values, but not with the ETP values. It thus seems that in AP 
the initiation of coagulation is hampered, while the thrombin generation capacity is not 
affected, and that the coagulation disturbances in AP are not primarily caused by the 
exhaustion of the coagulation factors in the plasma. This gradually hampered initiation of 
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coagulation is not caused by abnormally functioning APC in vitro, because the severity of AP 
did not correlate with lag time or ETP values in the presence of APC.  
It is possible that the gradually hampered initiation of coagulation, up until it is disrupted, is 
caused by TFPI. In fact, this seems to be the case. There was a significant increase in free 
TFPI levels with the severity of AP. The total TFPI levels were higher in patients with OF than 
in the group of patients composed of those with mild AP plus those with severe AP but 
without OF. However, there was no increase in these values between patients with mild AP 
and severe AP without OF. This increase, especially in free TFPI levels, seems to occur in 
those patients whose thrombogram lines were ‘flat’ because their free TFPI levels and TFPI 
ratios were significantly higher than those of the other patients. In AP, this increase in TFPI 
might compensate the rise of TF caused by inflammation. It is also possible that natural 
heparins and endothelial damage in AP lead to the release of TFPI from endothelium.  
Recombinant APC has been found to reduce the mortality rate of severe sepsis patients 
(Bernard et al 2001). Thus, generation and function of APC in AP are of great interest. In the 
first study we showed that in severe AP endogenous APC generation is upregulated but 
insufficient. In the fourth study we extended these findings by demonstrating that in vitro 
exogenous APC functions similarly, regardless of the severity of AP. Therefore, AP itself 
does not disrupt the function of APC. The value of this new information rises from the fact 
that acquired APC resistance might well occur in AP via disruptions in EPCR and protein C 
inhibitor. In experimental studies inflammatory mediators have been found to down-regulate 
EPCR expression (Esmon 1999), and EPCR can also be shed from endothelium by thrombin 
and inflammatory mediators (Esmon 2004a). 
 
3.4.2 Inflammatory markers in acute pancreatitis (II, III) 
In the second study we found that serum CD59 levels were significantly higher in patients 
with OF than in other AP patients. Increased plasma levels of CD59 apparently indicate the 
loss of CD59 from cell surfaces (Vakeva et al 1992; Rautemaa and Meri 1996). Loss of CD59 
may occur in the pancreas, in blood endothelium, blood cells or in tissues, such as the lung, 
that are affected in AP. Why are the levels of CD59 elevated in AP? The CD59 molecule has 
a GPI anchor by which it binds to phospholipids on the outer leaflet of cell membranes. Thus, 
CD59 might well be shed off by phospholipases (Morgan 1989; Vakeva et al 1992; Rautemaa 
and Meri 1996) e.g. by phosphatidylinositol-specific phospholipase D (PIPLD). Many 
phospholipases C (PIPLC) can also cleave the GPI anchor of CD59, but this dependens on 
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the type of anchorage and number of phospholipids on the CD59 molecule. Only a proportion 
of CD59 molecules are sensitive to PIPLC enzymes. In AP, phospholipases are released, 
and also membrane damage may occur. Loss of membrane integrity (and e.g. phospholipase 
A2) might lead to the release of cell membrane vesicles containing CD59. The CD59 
molecule can be cleaved by trypsin only when in reduced form, as it is generally relatively 
resistant to proteolytic enzymes (Meri et al 1996). Increased CD59 levels have been found 
also in humans during acute myocardial infarction, and myocardial damage has been found 
to lead to the release of CD59 from the sarcolemmal cell membrane (Vakeva et al 2000). A 
similar, yet more extensive and widespread process may thus be occurring in AP. Loss of 
CD59 is likely to predispose the cells to complement membrane damage and to inflammatory 
changes which the forming MAC complexes can induce. A tendency for increased 
complement activation has been observed in AP (Foulis et al 1982; Whicher et al 1982; 
Duchateau et al 1984; Roxvall et al 1989; Roxvall et al 1990) and is very likely due to the 
release of proteolytic enzymes from the pancreatic acinar cells.   
In the third study we found that the highest measured sRAGE level during the follow-up 
period was significantly higher in AP patients with OF than in AP patients who recovered 
without developing OF. Also the non-survivors had significantly higher maximum sRAGE 
levels than the survivors. RAGE is expressed on endothelium, neurons, vascular smooth 
muscle cells, and mononuclear phagocytes (Abeyama et al 2005; Li et al 2006). The 
circulating pool of sRAGE consists of esRAGE and proteolytically cleaved forms of RAGE 
(Hudson et al 2005). RAGE and sRAGE have been studied mostly in chronic diseases 
(Emanuele et al 2005; Falcone et al 2005; Pullerits et al 2005; Basta et al 2006) but little is 
still known about their function in patients. However, it seems that high levels of sRAGE (total 
pool) in severe AP could be caused by damage to the endothelium, or they could be 
released by activated cells. High levels of sRAGE have also been found in patients with 
sepsis (Bopp et al 2008) and acute lung injury (Uchida et al 2006). High amniotic fluid 
concentrations of sRAGE and esRAGE have been shown to be associated with intra-
amniotic infection or inflammation (Romero et al 2008), and administration of recombinant 
sRAGE has been found to reduce inflammatory responses (Wear-Maggitti et al 2004; 
Andrassy et al 2006; Bucciarelli et al 2006; Raman et al 2006). 
In the third study we also found that the HMGB1 levels of three different severity groups of 
AP patients were similar. This is in agreement with the study by Yasuda and colleagues 
(Yasuda et al 2006) who used a commercially available ELISA kit to determine the on-
admission serum HMGB1 levels. They found that the levels were higher in patients with 
organ dysfunction than in those without organ dysfunction, but the difference was not 
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significant. Furthermore, the HMGB1 levels in patients with pancreatic necrosis were similar 
to those in patients without pancreatic necrosis, and the levels in non-survivors were similar 
to those of survivors. Finally, the serum HMGB1 levels did not correlate with the Ranson 
score or APACHE II score. In this context it is noteworthy that the HMGB1 levels in systemic 
inflammation-related acute lung injury (Ueno et al 2004) determined by the Western 
immunoblotting method, were similar between survivors and non-survivors, and in the study 
on sepsis (Sunden-Cullberg et al 2006) no predictable correlation was found between the 
serum HMGB1 levels and the severity of sepsis. Although it is presently unclear how greatly 
the differences between the methods and between the specificities of the antibodies used 
affect the data (Sunden-Cullberg et al 2006), collectively, the above results support the view 
that HMGB1 levels in patients with AP, sepsis or acute lung injury neither correlate with the 
severity of the insult nor with the patients’ outcome. Three recent studies have compared 
different methods of analyzing HMGB1, and they have demonstrated a strong correlation 
between ELISA and the Western immunoblotting method in analyzing patient plasma 
(Sunden-Cullberg et al 2006; Ilmakunnas et al 2008; Karlsson et al 2008). HMGB1 may 
nevertheless play a role in the pathogenesis of systemic inflammation-related organ 
dysfunction. 
The cellular release of HMGB1 is associated with the post-translational modifications of the 
protein. Thus, HMGB1 molecules derived from necrotic cells and activated phagocytes are 
hypo-acetylated and hyper-acetylated, respectively. The two forms are considered to be 
molecularly distinct, and may differ in their inflammation-promoting capacity. (Bonaldi et al 
2003; Youn and Shin 2006) The administration of HMGB1 antagonists is beneficial in 
experimental models of sepsis and systemic inflammation (Wang et al 2004b; Chen et al 
2005; Lin et al 2005). Sawa and colleagues (Sawa et al 2006) used anti-HMGB1 neutralizing 
antibody in experimental AP, and found that it inhibited the elevation of serum amylase, 
alanine aminotransferase and creatinine, and decreased the histological alterations in the 
pancreas and the lung.  
 
3.4.3 Endothelial damage, coagulation and inflammation in acute 
pancreatitis (I-IV) 
In the pathogenesis of AP, the acinar cell injury causes leakage of pancreatic enzymes into 
pancreatic tissue, where they become activated and initiate autodigestion of the pancreas. 
The activated proteases break down tissue and cell membranes, causing edema, vascular 
damage, hemorrhage, necrosis and local inflammation. The microvascular derangement 
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propagates this event further. PC and APC can bind to EPCR, which enhances their activity. 
This APC-EPCR complex does not appear to display anticoagulant activity. EPCR can be 
shed from endothelium by thrombin and inflammatory mediators. (Esmon 2004a) CD59 can 
be shed from cells either in the form of small membrane vesicles or after cleavage by 
phospholipase C or D (Meri et al 1996). The circulating pool of sRAGE consists of esRAGE 
and proteolytically cleaved forms of RAGE (Hudson et al 2005). Intravascular TFPI is present 
in three different pools: the first pool is in the circulation (80% in complex with lipoproteins 
and about 5-20% free), the second is found in the cytoplasm of platelets, and the third, and 
the largest, pool is bound to the endothelium (DelGiudice and White 2009). Heparin and 
glycosaminoglycans, and probably endothelial damage, induce the release of free TFPI from 
the vessel wall (Sandset et al 1988).  
In this study, the AP patients with OF were found to have PC deficiency and decreased APC 
generation, increased serum levels of CD59, increased plasma levels of sRAGE and 
increased plasma levels of free TFPI. It thus seems that our findings in severe AP patients 
with OF could be explained by endothelial damage caused by AP. 
 
Patients with severe AP develop systemic inflammation, which is considered to play a role in 
the pathogenesis of MOF. OF mimics the process seen in patients with sepsis: it is 
characterized by an overwhelming production of mediators of inflammation, activation of the 
complement system and activation of coagulation. These pathways interact in many ways 
during systemic inflammation. The key factor linking inflammation and coagulation is TF, 
which is expressed by monocytes after cytokine stimulation, and exposed to blood after 
endothelial damage (Esmon 1999; Levi and van der Poll 2008). The induction of coagulation 
by TF leads to thrombin generation. Thrombin and proinflammatory cytokines then activate 
platelets (Dahlback 2000), and this further enhances TF expression (Mackman 2004). The 
function of natural anticoagulants is impaired by proinflammatory mediators, and the ongoing 
thrombin generation leads to their consumption thus lowering their levels (Esmon 2000; Levi 
and van der Poll 2008). In experimental studies, cytokines have been found to down-regulate 
TM and EPCR expression (Esmon 1999). EPCR can be shed from endothelium by thrombin 
and inflammatory mediators, and it can bind to activated neutrophils, inhibiting their 
extravasation (Esmon 2004a). TM can bind to and neutralize HMGB1 (Abeyama et al 2005; 
Esmon 2005b). The complement pathway regulator protein C4Bp binds to PS and diminishes 
its cofactor effect on PC (Vine 2009). Complement activation generates the MAC, which can 
expose the phosphatidylserine on the surface of the cells, where it can take part in the 
initiation and amplification of coagulation (Esmon 2004a). Thrombin activates TAFI, which is 
an inhibitor of the complement anaphylatoxin C5a (Esmon 2005a).  
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Naturally, all these interactions between inflammation and coagulation could, at least partly, 
explain our findings in the patients with severe AP. 
 
3.4.4 Limitations of the study 
The main limitation of this study is the relatively small number of patients in the four parts of 
the study. Therefore, regardless of our interesting findings about the inflammatory and 
coagulation disturbances in AP patients, and the association between the development of OF 
and fatal outcome, these findings should be confirmed in further studies with a larger number 
of patients. In addition to the small patient material, another limiting factor was the lack of 
sufficient samples during the study period. This was due mostly to the early discharge of the 
patients from hospital, but also some samples were lost during the storage period. 
In the coagulation studies, there may have been some confusion and limitations regarding 
the patients’ medications. Some patients may have used anticoagulants before admission to 
hospital, or may have received prophylactic medication for thrombosis, or coagulation 
products during their hospital stay. Some of the patients with alcohol-induced AP may have 
had nutritional deficiencies or liver failure, which may have influenced their coagulation 
capacity.  
In our coagulation studies we investigated thrombin generation capacity and two of the three 
endogenous anticoagulant pathways, namely PC and TFPI. However, we did not study AT, 
which also has a central role in the coagulation and inflammation processes. In these studies 
we could also have used the DIC score, which would have given us more information about 
the patients’ coagulation status.  
In our studies on inflammation markers, we measured the levels of HMGB1, which has been 
widely investigated in sepsis. This was logical, because the SIRS in AP resembles sepsis. 
RAGE is a receptor for HMGB1 and has a soluble form, sRAGE. High sRAGE levels have 
also been found in sepsis and acute lung failure, but chronic diseases have been the most 
frequent target of investigation. Because acute lung failure is the commonest OF in AP, we 
decided to study the sRAGE levels together with the HMGB1 levels. We found elevated 
sRAGE levels in AP patients with OF, and the levels were also higher in non-survivors than 
in survivors. However, only little is known about the functioning of sRAGEs in patients. So, 
despite our interesting findings, it is difficult to determine their clinical importance. On the 
other hand, it is known that CD59 deficiency in humans causes a disease called paroxysmal 
nocturnal hemoglobinuria, which is characterized by hemolytic anemia and thrombosis. 
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Similarly, mice deficient in AT, TFPI and PC die already in the uterus during embryonic 
development.  
 
3.4.5 Clinical and future aspects 
Despite the increasing knowledge of the pathogenesis of AP (mainly from animal studies) 
and OF, the treatment of AP has advanced only little, and is currently still mainly supportive. 
It is known that in AP, the development of OF is most important factor leading to morbidity 
and mortality. Especially if OF is present already at admission to hospital (early OF) and is 
persistent (lasting >48 h) the mortality rate is high, and in over half of the patients, OF 
progresses to MOF. Thus, early identification of patients who are likely to develop OF is 
important, so that aggressive supportive treatment could be started in the intensive care unit. 
It is noteworthy that the ‘time window’ for early recognition of these patients and 
commencement of the possible treatment is very short, probably less than 24 h.  
In this study, we tried to find inflammatory and coagulation markers that would predict the 
development of OF and fatal outcome in AP. All of the OF patients studied had acute lung 
failure, necessitating mechanical ventilation and/or renal failure necessitating hemodialysis. 
All of the patients with OF also had persistent OF. We found defects in the PC pathway, 
which were associated with the development of OF. Similarly, we found that high levels of 
free TFPI, sRAGE and CD59 were associated with the development of OF, and that high 
CD59 levels predicted the development of OF. The levels of free TFPI combined with a ‘flat 
curve’ in the thrombogram were also predictive for fatal outcome in AP. These findings might 
reflect endothelial damage caused by systemic activation of inflammation and coagulation in 
AP. However, before these markers could be considered as predictive for OF in clinical use, 
these findings should be confirmed in studies with a larger number of AP patients. Also, the 
used analytical methods are time-consuming or are not currently used in clinical practice, 
and thus are not feasible tools in emergency medicine. 
Could these findings be useful in therapeutic approaches? In experimental studies, 
administration of recombinant sRAGE and soluble CD59 has been shown to suppress the 
inflammatory response. The use of anti-HMGB1 neutralizing antibody was found to decrease 
histological alterations in pancreas in an experimental AP study. In a clinical study, 
recombinant APC has been shown to reduce mortality in sepsis patients. Similarly, 
administration of recombinant TFPI has been studied with controversial results in sepsis 
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patients. These findings should nevertheless be confirmed in large clinical trials with AP 
patients. 
In the future, it would seem profitable to study more closely the mechanisms behind the 
endothelial damage in SIRS and AP. By studying the linking factors between the coagulation 
and inflammatory cascades, it might be possible to find therapeutic agents and to start 
clinical trials. Currently, the natural anticoagulant pathways seem to be promising candidates 
for the clinical studies, because they express both anticoagulant and anti-inflammatory 
effects. Furthermore, the thrombogram method might offer a useful tool for investigating in 
more detail the kinetics of coagulation, and the coagulation disturbances in AP. 
 
3.5 Conclusions 
1. PC deficiency and decreased APC generation in severe AP probably contribute to 
compromised anticoagulant and anti-inflammatory defence. A new coagulation disturbance 
(i.e., TF-initiated thrombin generation delayed by TFPI release) in AP was characterized. 
2. Increased serum levels of complement regulator protein CD59, and increased plasma 
levels of sRAGE were found in patients with severe AP and OF. There was no significant 
difference in the HMGB1 levels between the severity groups of AP patients. Thus, CD59 and 
sRAGE may play a role in the pathogenesis of inflammation in these patients. 
3. The defects in the PC pathway and TFPI-release-induced delayed thrombin generation 
might be  associated with the development of OF in AP. Also, the increased levels of CD59 
and sRAGE seem to be associated with the development of OF in AP. The ‘flat curve’ in CAT 
combined with free TFPI (cutoff 25 ng/ml) seem to be predictive of fatal outcome. Also, the 
high sRAGE level might be predictive of fatal outcome.     
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